



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

14 November 2023
EMA/CHMP/439990/2023
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 11-14 September 2023

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	9
1.1.	Welcome and declarations of interest of members, alternates and experts.....	9
1.2.	Adoption of agenda	9
1.3.	Adoption of the minutes	9
2.	Oral Explanations	10
2.1.	Pre-authorisation procedure oral explanations.....	10
2.1.1.	Aqumeldi - enalapril maleate - PUMA - EMEA/H/C/005731	10
2.1.2.	sugammadex - EMEA/H/C/006115.....	10
2.2.	Re-examination procedure oral explanations	10
2.3.	Post-authorisation procedure oral explanations	10
2.3.1.	RoActemra - tocilizumab - EMEA/H/C/000955/II/0114	10
2.3.2.	Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan	11
2.3.3.	Translarna - ataluren - EMEA/H/C/002720/II/0069, Orphan.....	11
2.3.4.	Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan	12
2.4.	Referral procedure oral explanations	12
3.	Initial applications	12
3.1.	Initial applications; Opinions.....	12
3.1.1.	Aqumeldi - enalapril maleate - PUMA - EMEA/H/C/005731	12
3.1.2.	Catiolanze - latanoprost - EMEA/H/C/005933	13
3.1.3.	Ebglyss - lebrikizumab - EMEA/H/C/005894	13
3.1.4.	Finlee - dabrafenib - Orphan - EMEA/H/C/005885.....	14
3.1.5.	Herwenda - trastuzumab - EMEA/H/C/005769.....	14
3.1.6.	Vanflyta - quizartinib - Orphan - EMEA/H/C/005910.....	14
3.1.7.	Yorvipath - palopegteriparatide - Orphan - EMEA/H/C/005934	15
3.1.8.	Zilbrysq - zilucoplan - Orphan - EMEA/H/C/005450	15
3.1.9.	Zoonotic Influenza Vaccine Seqirus - zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) - EMEA/H/C/006375	16
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	16
3.2.1.	arpraziquantel - Article 58 - EMEA/H/W/004252	16
3.2.2.	azacitidine - EMEA/H/C/006154.....	17
3.2.3.	exagamglogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763.....	17
3.2.4.	elranatamab - PRIME - Orphan - EMEA/H/C/005908	17
3.2.5.	eribulin - EMEA/H/C/006134	18
3.2.6.	germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/006053.....	18
3.2.7.	ibuprofen - EMEA/H/C/006129	18

3.2.8.	paclitaxel - EMEA/H/C/006173	18
3.2.9.	leriglitzone - Orphan - EMEA/H/C/005757	19
3.2.10.	momelotinib - Orphan - EMEA/H/C/005768.....	19
3.2.11.	tofersen - Orphan - EMEA/H/C/005493.....	19
3.2.12.	ranibizumab - EMEA/H/C/006055	19
3.2.13.	rozanolixizumab - Orphan - EMEA/H/C/005824	20
3.2.14.	trametinib - Orphan - EMEA/H/C/005886.....	20
3.2.15.	ustekinumab - EMEA/H/C/006101.....	20
3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	21
3.3.1.	apadamtase alfa - Orphan - EMEA/H/C/006198	21
3.3.2.	efanesoctocog alfa - Orphan - EMEA/H/C/005968	21
3.3.3.	insulin icodec - EMEA/H/C/005978	21
3.3.4.	fidanacogene elaparvovec - PRIME - Orphan - ATMP - EMEA/H/C/004774.....	21
3.3.5.	Capivasertib - EMEA/H/C/006017	22
3.3.6.	dasatinib - EMEA/H/C/006251	22
3.3.7.	Eribulin - EMEA/H/C/006191	22
3.3.8.	Iptacopan - PRIME - Orphan - EMEA/H/C/005764	22
3.3.9.	rituximab - EMEA/H/C/006224	23
3.3.10.	denosumab - EMEA/H/C/005964	23
3.3.11.	omalizumab - EMEA/H/C/005958.....	23
3.3.12.	ustekinumab - EMEA/H/C/006183.....	23
3.3.13.	ustekinumab - EMEA/H/C/006415.....	23
3.3.14.	vibegron - EMEA/H/C/005957	24
3.3.15.	ustekinumab - EMEA/H/C/006132.....	24
3.3.16.	denosumab - EMEA/H/C/006378	24
3.4.	Update on on-going initial applications for Centralised procedure.....	24
3.4.1.	pomalidomide - EMEA/H/C/006195.....	24
3.4.2.	masitinib - Orphan - EMEA/H/C/005897	25
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004	25
3.5.1.	Albrioza - sodium phenylbutyrate / ursodoxicoltaurine - Orphan - EMEA/H/C/005901.....	25
3.5.2.	Krazati - adagrasib - EMEA/H/C/006013	25
3.6.	Initial applications in the decision-making phase.....	26
3.7.	Withdrawals of initial marketing authorisation application	26
3.7.1.	Vivjoa - oteseconazole - EMEA/H/C/005682	26
3.7.2.	SKYCovion - GBP510 - EMEA/H/C/005998	26

4.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	27
4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	27
4.1.1.	Cufence - trientine - EMEA/H/C/004111/X/0014/G	27
4.1.2.	Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/X/0033	27
4.1.3.	Kalydeco - ivacaftor - EMEA/H/C/002494/X/0114/G	28
4.1.4.	Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/X/0035	28
4.1.5.	Takhzyro - lanadelumab - Orphan - EMEA/H/C/004806/X/0034/G	28
4.1.6.	Vyvgart - efgartigimod alfa - Orphan - EMEA/H/C/005849/X/0003	29
4.1.7.	Xolair - omalizumab - EMEA/H/C/000606/X/0115/G	29
4.1.8.	Yuflyma - adalimumab - EMEA/H/C/005188/X/0022	30
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues	30
4.2.1.	Veltassa - patiromer - EMEA/H/C/004180/X/0031/G	30
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question	31
4.3.1.	Opdivo - nivolumab - EMEA/H/C/003985/X/0132	31
4.3.2.	Rozlytrek - entrectinib - EMEA/H/C/004936/X/0017/G	31
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	32
4.4.1.	Tecentriq - atezolizumab - EMEA/H/C/004143/X/0076	32
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	32
5.	Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008	33
5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information	33
5.1.1.	Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0107	33
5.1.2.	Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208/II/0023	33
5.1.3.	Carvykti - ciltacabtagene autoleucel - Orphan - ATMP - EMEA/H/C/005095/II/0021	34
5.1.4.	CellCept - mycophenolate mofetil - EMEA/H/C/000082/II/0170/G	34
5.1.5.	Cibinqo - abrocitinib - EMEA/H/C/005452/II/0010	35
5.1.6.	Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0027	35
5.1.7.	Evkeeza - evinacumab - EMEA/H/C/005449/II/0011	36
5.1.8.	Fexinidazole Winthrop - fexinidazole - EMEA/H/W/002320/II/0016	36
5.1.9.	HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0087	36
5.1.10.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0121	37
5.1.11.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0135	37

5.1.12.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0138	38
5.1.13.	Mounjaro - tirzepatide - EMEA/H/C/005620/II/0007.....	38
5.1.14.	Nordimet - methotrexate - EMEA/H/C/003983/II/0027.....	39
5.1.15.	Olumiant - baricitinib - EMEA/H/C/004085/II/0037	39
5.1.16.	Pepaxti - melphalan flufenamide - EMEA/H/C/005681/II/0002	40
5.1.17.	Rubraca - rucaparib - EMEA/H/C/004272/II/0036.....	40
5.1.18.	Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0013/G	41
5.1.19.	VeraSeal - human fibrinogen / human thrombin - EMEA/H/C/004446/II/0027	41
5.1.20.	Voxzogo - vosoritide - Orphan - EMEA/H/C/005475/II/0006	42
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	42
5.2.1.	Scenesse - afamelanotide - Orphan - EMEA/H/C/002548/II/0044	42
5.2.2.	Valdoxan - agomelatine - EMEA/H/C/000915/II/0051	43
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	43

6. Medical devices 43

6.1.	Ancillary medicinal substances - initial consultation	43
6.2.	Ancillary medicinal substances – post-consultation update.....	44
6.3.	Companion diagnostics - initial consultation	44
6.3.1.	in vitro diagnostic medical device - EMEA/H/D/006340.....	44
6.3.2.	in vitro diagnostic medical device - EMEA/H/D/006308.....	44
6.3.3.	in vitro diagnostic medical device - EMEA/H/D/006310.....	44
6.4.	Companion diagnostics – follow-up consultation.....	44

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 45

7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use).....	45
-------------	---	-----------

8. Pre-submission issues 45

8.1.	Pre-submission issue.....	45
8.1.1.	elafibranor - Orphan - H0006231.....	45
8.1.2.	chikungunya virus, strain chikv Ir2006-opy1, live attenuated - H0005797.....	45
8.2.	Priority Medicines (PRIME).....	45

9. Post-authorisation issues 46

9.1.	Post-authorisation issues	46
9.1.1.	Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan	46
9.1.2.	Translarna - ataluren - EMEA/H/C/002720/II/0069, Orphan.....	46
9.1.3.	Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan	47
9.1.4.	Ninlaro - ixazomib - EMEA/H/C/003844/II/0045, Orphan.....	47

9.1.5.	Dovprela - pretomanid - EMEA/H/C/005167/II/0013, Orphan.....	48
9.1.6.	Ofev – nintedanib – EMEA/H/C/003821 LEG/006	48
9.1.7.	Brilique - ticagrelor - EMEA/H/C/001241/II/0061.....	49
9.1.8.	Pandemic Influenza Vaccine H5N1 Baxter - Pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) – EMEA/H/C/001200	49
9.1.9.	Bimervax - sars-cov-2 virus, variants b.1.351-b.1.1.7, spike protein, receptor binding domain fusion heterodimer - EMEA/H/C/006058/II/0004	49
9.1.10.	Amyvid - Florbetapir (18F) - EMEA/H/C/002422/II/0044	50
9.1.11.	Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/S/0004.....	50
9.1.12.	Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/II/0006	50
9.1.13.	Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0038, Orphan.....	50
9.1.14.	RoActemra - tocilizumab - EMEA/H/C/000955/II/0114	51

10. Referral procedures 52

10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004	52
10.1.1.	Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065	52
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 .	53
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	53
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC	53
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	53
10.5.1.	Havrix - EMEA/H/A-30/1527	53
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC	53
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	54
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC	54
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	54
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	54
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	54

11. Pharmacovigilance issue 54

11.1.	Early Notification System	54
--------------	--	-----------

12. Inspections 54

12.1.	GMP inspections	54
12.2.	GCP inspections	54
12.3.	Pharmacovigilance inspections.....	55

12.4.	GLP inspections	55
13.	Innovation Task Force	55
13.1.	Minutes of Innovation Task Force.....	55
13.2.	Innovation Task Force briefing meetings.....	55
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004	55
13.4.	Nanomedicines activities	55
14.	Organisational, regulatory and methodological matters	55
14.1.	Mandate and organisation of the CHMP	55
14.1.1.	Vote by proxy	55
14.1.2.	CHMP membership.....	55
14.1.3.	CHMP co-opted membership	56
14.2.	Coordination with EMA Scientific Committees.....	56
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)	56
14.2.2.	Paediatric Committee (PDCO).....	56
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	56
14.3.1.	Biologics Working Party (BWP)	56
14.3.2.	Scientific Advice Working Party (SAWP).....	57
14.3.3.	Election of Biosimilar Medicinal Product Working Party (BMWP) vice-chairperson	57
14.3.4.	Election of Quality Working Party (QWP) vice-chairperson.....	57
14.3.5.	Election of Biologics Working Party (BWP) vice-chairperson.....	57
14.3.6.	Q&A on Model informed drug development (MIDD) in neonates	57
14.4.	Cooperation within the EU regulatory network.....	58
14.5.	Cooperation with International Regulators.....	58
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	58
14.7.	CHMP work plan	58
14.7.1.	CHMP Work Plan 2023	58
14.8.	Planning and reporting	58
14.8.1.	Update of the Business Pipeline report for the human scientific committees	58
14.9.	Others	58
15.	Any other business	59
15.1.	AOB topic.....	59
15.1.1.	Update on COVID-19	59
15.1.2.	Nitrosamine Q&A update	59

List of Participants	60
Explanatory notes	67

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 11-14 September 2023.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 17-20 July 2023 Plenary and 14-17 August 2023 Written Procedure.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 04 September 2023.

The CHMP adopted the CHMP minutes for 17-20 July 2023 Plenary and 14-17 August 2023 Written Procedure.

The CHMP adopted the minutes from the PROM meeting held on 04 September 2023.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. Aqumeldi - enalapril maleate - PUMA - EMEA/H/C/005731

Proveca Pharma Limited; treatment of heart failure

Scope: Oral explanation

Action: Oral explanation to be held on 13 September 2023 at 09:00

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.06.2023, 25.05.2023, 23.02.2023. List of Questions adopted on 21.07.2022.

An oral explanation was held on 13 September 2023. The presentation by the applicant focused on quality aspects.

See 3.1

2.1.2. sugammadex - EMEA/H/C/006115

reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: Oral explanation

Action: Oral explanation to be held on 12 September 2023 at 11:00

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

An oral explanation was held on 12 September 2023. The presentation by the applicant focused on quality and procedural aspects.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. RoActemra - tocilizumab - EMEA/H/C/000955/II/0114

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension of indication to include treatment of new indication for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) for RoActemra, based on final results from the pivotal Phase III study WA29767 (focuSSced) entitled, "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of

Tocilizumab Versus Placebo in Patients With Systemic Sclerosis” and the supportive Phase II/III study WA27788 (faSScinate) entitled, “A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis”.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 28 of the RMP has also been submitted.”

Scope: Oral explanation

Action: Oral explanation to be held on 11 September 2023 at 16:00

Request for Supplementary Information adopted on 26.04.2023, 15.12.2022.

An oral explanation was held on 11 September 2023. The presentation by the MAH focused on clinical aspects.

See 9.1

2.3.2. Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan

PTC Therapeutics International Limited

Rapporteur: Peter Mol, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Oral explanation

Action: Oral explanation to be held on 12 September 2023 at 14:00

Request for Supplementary Information adopted on 25.05.2023.

An oral explanation was held on 12 September 2023. The presentation by the MAH focused on clinical and methodological aspects and in particular the results from study 041, results from a meta-analysis including studies 007, 020 and 041 as well as results from STRIDE registry (study 025).

See 9.1

2.3.3. Translarna - ataluren - EMEA/H/C/002720/II/0069, Orphan

PTC Therapeutics International Limited

Rapporteur: Peter Mol, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: “Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information following results from study PTC124-GD-041-DMD, listed as a specific obligation in the Annex II; This is a Phase 3 multicentre, randomised, double-blind, 18-month, placebo-controlled study, followed by a 18-month open label extension to confirm the efficacy and safety of ataluren in the treatment of ambulant patients with mnDMD aged 5 years or older.

Annex II, and Annex IIB are updated to delete the SOB and to reflect the switch from conditional to full marketing authorisation.

The Package Leaflet is updated accordingly. The RMP version 11.0 has also been submitted. Minor corrections were done to align the PI with the latest QRD templates.”

Scope: Oral explanation

Action: Oral explanation to be held on 12 September 2023 at 14:00

Request for Supplementary Information adopted on 25.05.2023.

An oral explanation was held on 12 September 2023. The presentation by the MAH focused on clinical aspects and in particular the results from study 041.

See 9.1

2.3.4. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan

GlaxoSmithKline (Ireland) Limited

Rapporteur: Johanna Lähteenvuo, Co-Rapporteur: Carolina Prieto Fernandez, PRAC

Rapporteur: Ulla Wändel Liminga

Scope: Oral explanation

Action: Oral explanation to be held on 12 September 2023 at 09:00

Request for Supplementary Information adopted on 26.04.2023.

An oral explanation was held on 12 September 2023. The presentation by the MAH focused on clinical aspects.

See 9.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Aqumeldi - enalapril maleate - PUMA - EMEA/H/C/005731

Proveca Pharma Limited; treatment of heart failure

Scope: opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.06.2023, 25.05.2023, 23.02.2023. List of Questions adopted on 21.07.2022.

See 2.1

An oral explanation was held on 13 September 2023. The presentation by the applicant focused on quality aspects.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a paediatric use marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 13 September 2023.

The summary of opinion was circulated for information.

3.1.2. [Catiolanze - latanoprost - EMEA/H/C/005933](#)

Santen Oy; Reduction of elevated intraocular pressure (IOP)

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.06.2023. List of Questions adopted on 26.01.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.3. [Ebglyss - lebrikizumab - EMEA/H/C/005894](#)

Almirall, S.A.; Treatment of moderate-to-severe atopic dermatitis in adults and adolescents

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.07.2023. List of Questions adopted on 23.02.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that lebrikizumab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 8 September 2023.

The summary of opinion was circulated for information.

3.1.4. [Finlee - dabrafenib - Orphan - EMEA/H/C/005885](#)

Novartis Europharm Limited; Treatment of glioma

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 26.01.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.5. [Herwenda - trastuzumab - EMEA/H/C/005769](#)

Sandoz GmbH; treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 15.12.2022. List of Questions adopted on 19.05.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 5 September 2023.

The summary of opinion was circulated for information.

3.1.6. [Vanflyta - quizartinib - Orphan - EMEA/H/C/005910](#)

Daiichi Sankyo Europe GmbH; Treatment of adult patients with diagnosed acute myeloid leukaemia (AML)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.07.2023, 25.05.2023. List of Questions adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that quizartinib is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 8 September 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.7. [Yorvipath - palopegteriparatide - Orphan - EMEA/H/C/005934](#)

Ascendis Pharma Bone Diseases A/S; PTH replacement therapy indicated for the treatment of hypoparathyroidism in adults.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.07.2023. List of Questions adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that palopegteriparatide is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.8. [Zilbrysq - zilucoplan - Orphan - EMEA/H/C/005450](#)

UCB Pharma S.A.; treatment of generalised myasthenia gravis in adults

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.06.2023. List of Questions adopted on 26.01.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that zilucoplan is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 8 September 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.9. [Zoonotic Influenza Vaccine Seqirus - zoonotic influenza vaccine \(H5N1\) \(surface antigen, inactivated, adjuvanted\) - EMEA/H/C/006375](#)

Seqirus S.r.l., active immunisation against H5 subtype of Influenza A virus

Scope: Opinion

Action: For adoption

Informed consent application (Article 10c of Directive No 2001/83/EC), Informed Consent of Aflunov

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.2. **Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)**

3.2.1. [arpraziquantel - Article 58 - EMEA/H/W/004252](#)

treatment of schistosomiasis in children

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. azacitidine - EMEA/H/C/006154

Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 26.04.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. exagamglogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763

Vertex Pharmaceuticals (Ireland) Limited; treatment of transfusion-dependent β -thalassemia and sickle cell disease

Scope: List of outstanding issues

Action: For information

List of Questions adopted on 17.05.2023.

The CHMP was updated on discussions at the CAT. The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee endorsed the list of outstanding issues with a specific timetable as adopted by CAT.

3.2.4. elranatamab - PRIME - Orphan - EMEA/H/C/005908

Pfizer Europe MA EEIG; Treatment of adult patients with relapsed or refractory multiple myeloma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.05.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. eribulin - EMEA/H/C/006134

treatment of breast cancer and liposarcoma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.02.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/006053

indicated for in vitro radiolabelling of specific carrier molecules to be used for positron emission tomography (PET) imaging

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 26.04.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. ibuprofen - EMEA/H/C/006129

Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. paclitaxel - EMEA/H/C/006173

treatment of metastatic breast cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.05.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.9. leriglitzone - Orphan - EMEA/H/C/005757

Minoryx Therapeutics S.L.; the treatment of cerebral progression and myelopathy in male patients with adrenoleukodystrophy (ALD).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.12.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. momelotinib - Orphan - EMEA/H/C/005768

Glaxosmithkline Trading Services Limited; treatment of disease-related splenomegaly or symptoms and anaemia

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.11. tofersen - Orphan - EMEA/H/C/005493

Biogen Netherlands B.V.; treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult a SAG and adopted a list of questions to this group.

3.2.12. ranibizumab - EMEA/H/C/006055

treatment of neovascular age-related macular degeneration (AMD)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.02.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. rozanolixizumab - Orphan - EMEA/H/C/005824

UCB Pharma; Treatment of generalised myasthenia gravis (gMG)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.14. trametinib - Orphan - EMEA/H/C/005886

Novartis Europharm Limited; Treatment of paediatric patients aged 1 year and older with glioma

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 26.01.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.15. ustekinumab - EMEA/H/C/006101

treatment of plaque psoriasis, arthritis psoriatic, Crohn's Disease and ulcerative colitis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the BMWP and the MWP.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. apadamtase alfa - Orphan - EMEA/H/C/006198

Takeda Manufacturing Austria AG; treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. efanesoctocog alfa - Orphan - EMEA/H/C/005968

Swedish Orphan Biovitrum AB (publ); Treatment and prophylaxis of bleeding in patients with haemophilia A

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. insulin icodec - EMEA/H/C/005978

treatment of diabetes mellitus in adults

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. fidanacogene elaparvovec - PRIME - Orphan - ATMP - EMEA/H/C/004774

Pfizer Europe MA EEIG; indicated for the treatment of severe and moderately severe haemophilia B

Scope: List of questions

Action: For information

The CHMP was updated on discussions at the CAT. The Committee discussed the issues identified in this application.

The Committee endorsed the recommendation and scientific discussion together with the

list of questions as adopted by CAT.

3.3.5. Capiwasertib - EMEA/H/C/006017

is indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. dasatinib - EMEA/H/C/006251

Indicated for the treatment of chronic myelogenous leukaemia (CML)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. Eribulin - EMEA/H/C/006191

treatment of breast cancer and liposarcoma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. Iptacopan - PRIME - Orphan - EMEA/H/C/005764

Novartis Europharm Limited; treatment of paroxysmal nocturnal haemoglobinuria

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. rituximab - EMEA/H/C/006224

treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL) and Rheumatoid arthritis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. denosumab - EMEA/H/C/005964

treatment of osteoporosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.11. omalizumab - EMEA/H/C/005958

treatment of asthma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.12. ustekinumab - EMEA/H/C/006183

treatment of Crohn's disease, Ulcerative colitis, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.13. ustekinumab - EMEA/H/C/006415

treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults and Crohn's Disease

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.14. vibegron - EMEA/H/C/005957

treatment of micturition frequency and/or urgency incontinence as may occur in adult patients with Over Active Bladder (OAB) syndrome.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.15. ustekinumab - EMEA/H/C/006132

treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults, Crohn's Disease and ulcerative colitis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.16. denosumab - EMEA/H/C/006378

prevention of skeletal related events with advanced malignancies

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. pomalidomide - EMEA/H/C/006195

in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma (MM)

Scope: Change of timetable to respond to the list of questions adopted in July 2023

Action: For information

List of Questions adopted on 20.07.2023.

The CHMP noted the change of the timetable.

3.4.2. masitinib - Orphan - EMEA/H/C/005897

AB Science; in combination with riluzole for the treatment of adult patients with amyotrophic lateral sclerosis (ALS)

Scope: Letter by the applicant dated 07.09.2023 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in May 2023.

Action: For adoption

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

The CHMP agreed to the request for an extension to the clock stop to respond to the list of outstanding issues adopted in May 2023.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Albrioza - sodium phenylbutyrate / ursodoxicoltaurine - Orphan - EMEA/H/C/005901

Amylyx Pharmaceuticals EMEA B.V.; treatment of amyotrophic lateral sclerosis (ALS)

Scope: Start of procedure, re-examination timetable, third party intervention, list of questions to the SAG-N

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion on 22.06.2023. List of Outstanding Issues adopted on 23.02.2023, 10.11.2022. List of Questions adopted on 23.06.2022.

The CHMP noted the third party intervention.

The CHMP adopted a list of questions to the SAG-Neurology and endorsed the re-examination timetable.

3.5.2. Krazati - adagrasib - EMEA/H/C/006013

Mirati Therapeutics B.V.; treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation

Scope: Start of procedure, re-examination timetable, appointment of re-examination rapporteurs

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 20.07.2023. List of Outstanding Issues adopted on 25.05.2023, 23.02.2023. List of Questions adopted on 15.09.2022.

The CHMP appointed a Re-examination Rapporteur and a Re-examination Co-Rapporteur.

The CHMP endorsed the re-examination timetable.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. [Vivjoa - oteseconazole - EMEA/H/C/005682](#)

Gedeon Richter Plc.; treatment and prevention of recurrent vulvovaginal candidiasis (RVVC) including the acute episodes of RVVC in adult women

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.09.2022.

The CHMP noted the withdrawal of the marketing authorisation application.

3.7.2. [SKYCovion - GBP510 - EMEA/H/C/005998](#)

SK Chemicals GmbH; prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 15.12.2022.

The CHMP noted the withdrawal of the marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Cufence - trientine - EMEA/H/C/004111/X/0014/G

Univar Solutions BV

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension application to add a new strength (100 mg capsule, hard) grouped with a type IA variation (B.II.b.4.b) The RMP (version 1.3) is updated in accordance. The marketing authorisation holder took the opportunity to align the PI to the latest QRD template (version 10.3)."

Action: For adoption

List of Questions adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.2. Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/X/0033

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Peter Mol, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new pharmaceutical form (granules) associated with 2 new strengths (60 mg/40 mg/80 mg and 75 mg/50 mg/100 mg) to support a new indication in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene (see section 5.1). The new indication is only applicable to the new granules pharmaceutical form. As a consequence of the line extension the PI for the film coated tablets is also updated to reflect the addition of a new pharmaceutical form. The RMP (version 6.2) has also been submitted."

Action: For adoption

List of Outstanding Issues adopted on 20.07.2023. List of Questions adopted on 26.04.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.1.3. Kalydeco - ivacaftor - EMEA/H/C/002494/X/0114/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Beata Maria Jakline Ullrich, PRAC Rapporteur: Monica Martinez Redondo

Scope: "Extension application to add a new strength (59.5 mg) of the granules pharmaceutical form grouped with C.I.6.a, to support a new indication in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene (see section 5.1).

The RMP (version 15.1) has also been submitted.

Type IB B.II.f.1.b

The Product information has been updated accordingly."

Action: For adoption

List of Outstanding Issues adopted on 20.07.2023. List of Questions adopted on 26.04.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.1.4. Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/X/0035

Eurocept International B.V.

Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (350 mg/ml oral solution). The RMP (version 0.1) is updated in accordance."

Action: For adoption

List of Questions adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the similarity assessment report.

4.1.5. Takhzyro - lanadelumab - Orphan - EMEA/H/C/004806/X/0034/G

Takeda Pharmaceuticals International AG Ireland Branch

Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension application to add a new strength of 150 mg for lanadelumab solution for injection in pre-filled syringe and to extend the indication to include paediatric use (2 to <12 years). The new indication is only applicable to the new 150 mg strength

presentations.

The RMP (version 3.0) is updated in accordance.

A type IB variation (C.I.z) has been submitted to update section 7 of the Package Leaflet (PL) for the 300 mg in 2 ml pre-filled syringe (EU/1/18/1340/004-006) in line with the proposed PL for the 150 mg in 1 ml pre-filled syringe (new strength).

In addition, the MAH has requested an extension of the Orphan Market Exclusivity from 10 to 12 years.”

Action: For adoption

List of Outstanding Issues adopted on 20.07.2023. List of Questions adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.1.6. Vyvgart - efgartigimod alfa - Orphan - EMEA/H/C/005849/X/0003

Argenx

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald

Scope: “Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (1000 mg) and a new route of administration (subcutaneous use).”

Action: For adoption

List of Outstanding Issues adopted on 20.07.2023. List of Questions adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendation dated 7 September 2023.

4.1.7. Xolair - omalizumab - EMEA/H/C/000606/X/0115/G

Novartis Europharm Limited

Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn

Scope: “Extension application to add a new strength of 300 mg (150 mg/ml) for Xolair solution for injection grouped with quality type II, IB and IAIN variations. The RMP (version 17.0) is updated in accordance.”

Action: For adoption

List of Outstanding Issues adopted on 22.06.2023. List of Questions adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.8. Yuflyma - adalimumab - EMEA/H/C/005188/X/0022

Celltrion Healthcare Hungary Kft.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Mari Thorn

Scope: "Extension application to add a new strength (20 mg solution for injection). The indications for the new strength are identical to those already approved for the 40 mg strength.

The RMP (version 2.1) has also been submitted."

Action: For adoption

List of Questions adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.2. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues**

4.2.1. Veltassa - patiomer - EMEA/H/C/004180/X/0031/G

Vifor Fresenius Medical Care Renal Pharma France

Rapporteur: Jayne Crowe, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension application to introduce a new strength (1 g powder for oral suspension), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of population from 6 to 18 years old for Veltassa based on final results from paediatric study RLY5016-206P (EMERALD); this is a phase 2, open-label, multiple dose study to evaluate the pharmacodynamic effects, safety and tolerability of patiomer for oral suspension in children and adolescents 2 to less than 18 years of age with chronic kidney disease and hyperkalaemia. As a consequence, sections 1, 2, 4.1, 4.2, 4.8, 4.9, 5.1 and 6.5 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes."

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues relating to clinical aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Opdivo - nivolumab - EMEA/H/C/003985/X/0132

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Martin Huber

Scope: quality variation

Action: For adoption

The Committee discussed the issues identified in this application, relating to the orphan similarity.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Rozlytrek - entrectinib - EMEA/H/C/004936/X/0017/G

Roche Registration GmbH

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to:

1) Introduce a new pharmaceutical form (coated granules) associated with a new strength (50 mg).

2) Introduce a new route of administration (gastroenteral use) for the already authorised 100 mg and 200 mg hard capsules presentations.

The above two line extensions are grouped with 3 type II variations:

- C.I.6.a - To extend the currently approved indication in solid tumours with NTRK gene fusion to patients from birth to 12 years of age (both for the coated granules and already approved hard capsules presentations).

- C.I.6.a - To add a new paediatric indication from birth to 18 years of age for patients with solid tumours with a ROS1 gene fusion (both for the coated granules and already approved hard capsules presentations).

Based on final results from studies CO40778 (STARTRK-NG), GO40782 (STARTRK-2) and BO41932 (TAPISTRY). Study CO40778 is a Phase I/II open-label, dose-escalation and expansion study of entrectinib in pediatrics with locally advanced or metastatic solid or primary CNS tumors and/or who have no satisfactory treatment options; Study GO40782 is an open-label, multicenter, global Phase II basket study of entrectinib for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement (fusion), and study BO41932 is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay.

As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated accordingly. The Package Leaflet and Labelling are updated in accordance.

- C.I.4 - To add wording regarding the option of suspension in water of the content of the

capsules to be used orally or via the e.g., gastric or nasogastric tube (in sections 4.2 and 5.2 of the SmPC).

The RMP (version 5) is updated in accordance.

The MAH took the opportunity to introduce minor editorial changes to the PI and to update Annex II of the SmPC.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Tecentriq - atezolizumab - EMEA/H/C/004143/X/0076

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: “Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (1875 mg) and new route of administration (subcutaneous use). The RMP (version 24.0) is updated in accordance.”

Request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in July 2023.

Action: For adoption

List of outstanding issues adopted on 20.07.2023. List of Questions adopted on 30.03.2023.

The CHMP agreed to the request for an extension to the clock stop to respond to the list of outstanding issues adopted in July 2023.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0107

Takeda Pharma A/S

Rapporteur: Peter Mol

Scope: "Extension of indication to include treatment of adult patients with previously untreated CD30+ advanced (including Stage III) Hodgkin lymphoma (HL), in combination with doxorubicin, vinblastine and dacarbazine (AVD), for Adcetris, based on the second interim analysis of OS data from ECHELON-1 study (C25003); this is a randomized, open-label, phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical HL. As a consequence, sections 4.1 and 5 of the SmPC are updated."

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.2. Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208/II/0023

Blueprint Medicines (Netherlands) B.V.

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with indolent systemic mastocytosis (ISM) for avapritinib based on results from the pivotal part of study BLU-285-2203 (PIONEER), this is a 3-part, randomized, double-blind, placebo-controlled, Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 26.04.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.3. Carvykti - ciltacabtagene autoleucel - Orphan - ATMP - EMEA/H/C/005095/II/0021

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Scope: "Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an IMiD and a PI, have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for Carvykti, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomized, open-label, multicentre study to determine whether treatment with cilta-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the PI. As part of the application the MAH is requesting a 1-year extension of the market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The CHMP was updated on discussions at CAT. The Committee discussed the issues identified in this application relating to clinical aspects and the request for 1 year of market protection.

The Committee endorsed the request for supplementary information with a specific timetable as adopted by CAT.

5.1.4. CellCept - mycophenolate mofetil - EMEA/H/C/000082/II/0170/G

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher

Scope: "C.I.6.a: Extension of indication to include paediatric patients (3 months to 18 years of age) for hepatic and cardiac transplants and to extend the indication for renal transplants for paediatric patients starting from 3 months, based on pharmacokinetic data, published literature and the Roche Global Safety Database. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly.

Type IB (C.I.z): To update section 4.2 of the SmPC for the CellCept 500 mg tablets formulation in order to be in line with the other three CellCept formulations. And for alignment with the current QRD guidance, the Package Leaflet was updated to cross reference section 2 in section 6 for sodium content.

In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring the PI in line with the latest QRD template version 10.3."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted request for supplementary information with a specific timetable.

5.1.5. Cibinco - abrocitinib - EMEA/H/C/005452/II/0010

Pfizer Europe MA EEIG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis for Cibinco based on final results from non-clinical study 00655292 [21GR211] and interim results from clinical study B7451015; this is a Phase III multi-center, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to non-clinical and clinical aspects.

The Committee adopted request for supplementary information with a specific timetable.

5.1.6. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0027

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Peter Mol, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include the indication treatment of non-small cell lung cancer for Enhertu (trastuzumab deruxtecan), based on results from study DS8201-A-U204 (DESTINY-Lung01) and study DS8201-A-U206 (DESTINY-Lung02).

Study DESTINY-Lung01 is a phase 2, multicentre, open-label, 2-cohort study of trastuzumab deruxtecan (DS-8201a), an anti-HER2 antibody drug conjugate (ADC), for HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer (NSCLC) conducted at sites in Japan, the United States and Europe.

Study DESTINY-Lung02 is an ongoing phase 2, multicentre, randomised study to evaluate the safety and efficacy of trastuzumab deruxtecan in subjects with HER2-mutated metastatic non-small cell lung cancer, conducted in North America, Europe and Asia-Pacific. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendations dated 14 September 2023.

The summary of opinion was circulated for information.

5.1.7. Evkeeza - evinacumab - EMEA/H/C/005449/II/0011

Ultragenyx Germany GmbH

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Mari Thorn

Scope: "Extension of indication to include the treatment of paediatric patients with homozygous familial hypercholesterolaemia (HoFH) aged 5 years and older for Evkeeza, based on interim results from study R1500-CL-17100, as well as supportive information from an updated interim analysis of study R1500-CL-1719, and an extrapolation analysis (including population PK, population PK/PD, and simulation analyses). R1500-CL-17100 is an ongoing multicentre, three-part, single-arm, open-label study evaluating the efficacy, safety, and tolerability of evinacumab in paediatric patients aged ≥ 5 to 11 years with HoFH. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to introduce minor editorial changes to the PI. Furthermore, the PI is brought in line with the latest QRD template version 10.3."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Fexinidazole Winthrop - fexinidazole - EMEA/H/W/002320/II/0016

Sanofi Winthrop Industrie

Rapporteur: Fátima Ventura, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of both first stage (haemo-lymphatic) and second stage (meningo-encephalitic) of human African trypanosomiasis (HAT) due to *Trypanosoma brucei rhodesiense* for Fexinidazole Winthrop based on final results from study DNDI-FEX-07-HAT - Efficacy and safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to *Trypanosoma brucei rhodesiense*: a multicentre, open-label clinical trial; this is a phase-II/III, multicenter, open-label, non-randomized, single-arm clinical trial to assess the efficacy and safety of fexinidazole in patients with r-HAT. As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0087

Baxalta Innovations GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension of indication to include treatment of Chronic Inflammatory Demyelinating

Polyneuropathy (CIDP) in adults for HyQvia, based on final results from studies 161403 and ABV-771-1001; and interim results from study 161505. 161403 and 161505 are interventional Phase III efficacy and safety studies respectively, while ABV-771-1001 is an interventional Phase I safety study. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 14.0 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023.

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.10. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0121

Merck Sharp & Dohme B.V.

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with Stage IB (T2a ≥ 4 cm), II or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection, based on study KEYNOTE-091; an ongoing Phase 3, randomized, triple-blinded, placebo-controlled, multicenter study of pembrolizumab versus placebo in patients with early-stage NSCLC after resection and completion of standard adjuvant therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Package Leaflet is updated in accordance. An updated RMP version 39.1 was also submitted.”

Action: For adoption

Request for Supplementary Information adopted on 13.10.2022, 21.07.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.11. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0135

Merck Sharp & Dohme B.V.

Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include in combination with chemotherapy the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults based on study KEYNOTE-859, a randomized, double-blind phase 3 trial, evaluating Keytruda in combination with chemotherapy compared to placebo in combination with chemotherapy for the first-line treatment of patients with HER2-negative locally advanced unresectable or metastatic

gastric or GEJ adenocarcinoma. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet and Annex II are updated in accordance. Version 42.1 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.12. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0138

Merck Sharp & Dohme B.V.

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include Keytruda in combination with gemcitabine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on final results from study KEYNOTE-966; this is a Phase 3 randomized, double-blind study of Pembrolizumab plus Gemcitabine/Cisplatin versus Placebo plus Gemcitabine/Cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. As a consequence, sections 4.1, 4.4 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 43.1 of the RMP has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.13. Mounjaro - tirzepatide - EMEA/H/C/005620/II/0007

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include chronic weight management, including weight loss and weight maintenance, for Mounjaro, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥ 30 kg/m² (obesity), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition, based on a global, pivotal phase 3 study I8F-MC-GPHK (SURMOUNT-1) and five supportive phase 3 studies (SURPASS-1 to -5) in participants with T2DM and BMI ≥ 27 kg/m². SURMOUNT-1 is a phase 3, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of tirzepatide once weekly in participants without type 2 diabetes who have obesity or are overweight with weight related comorbidities. As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.14. Nordimet - methotrexate - EMEA/H/C/003983/II/0027

Nordic Group B.V.

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of moderate psoriasis in adults who are candidates for systemic therapy based on literature; As a consequence, sections 4.1, 4.2 and 4.9 of the SmPC were updated. The package leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023, 23.02.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.15. Olumiant - baricitinib - EMEA/H/C/004085/II/0037

Eli Lilly Nederland B.V.

Rapporteur: Peter Mol, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include the treatment of paediatric patients (from 2 years of age and older) with moderate to severe atopic dermatitis for Olumiant, based on the final results from study I4V-MC-JAIP; this is a Phase III, multicentre, randomised, double blind, placebo controlled, parallel-group, outpatient study evaluating the pharmacokinetics, efficacy and safety of baricitinib in paediatric patients with moderate-to-severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet has been updated accordingly. The RMP Version 21.2 is acceptable.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.16. [Pepaxti - melphalan flufenamide - EMEA/H/C/005681/II/0002](#)

Oncopeptides AB

Rapporteur: Peter Mol, Co-Rapporteur: Elita Poplavska, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of patients with Multiple Myeloma who have received at least two prior lines of therapies for Pepaxti, based on final results from study OP-103 OCEAN; this is a randomized, open-label phase III study in patients with relapsed or refractory multiple myeloma following two to four lines of prior therapies and who were refractory to lenalidomide and the last line of therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023, 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.17. [Rubraca - rucaparib - EMEA/H/C/004272/II/0036](#)

Zr Pharma& GmbH

Rapporteur: Carolina Prieto Fernandez, Co-Rapporteur: Peter Mol, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include maintenance treatment of adult patients with advanced (FIGO Stages III and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy for Rubraca, based on interim results from study CO-338-087 (ATHENA); this is a Phase III, randomized, double-blind, dual placebo controlled study of rucaparib as monotherapy and in combination with nivolumab in patients with newly diagnosed EOC, FTC or PPC who have responded to their first-line treatment (surgery and platinum-based chemotherapy). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.3 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023, 15.12.2022.

The Committee discussed the issues identified in this application relating to clinical aspects. The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.18. [Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0013/G](#)

Gedeon Richter Plc.

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include symptomatic treatment of endometriosis for Ryeqo in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis, based on final results from studies MVT-601-3101 and MVT-601-3102 and final results up to 104 weeks from study MVT-601-3103. Studies 3101 and 3102 are pivotal, phase III, randomised, double-blind, placebo-controlled, safety and efficacy studies to evaluate relugolix with E2 and NETA as a combination therapy for pain associated with endometriosis. Study 3103 is an open-label extension study including patients who completed one of the two pivotal studies and met the eligibility criteria, regardless of their treatment assignment in the pivotal studies. In the extension part all patients received relugolix combination therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC were updated. The Package Leaflet is updated in accordance. Update of section 4.5 of the SmPC to update information regarding Drug-Drug Interaction based on final results of DDI studies MVT-601-54, MVT-601-55 and MVT-601-57. Study MVT-601-54 is a 2-part interventional open-label study to assess the potential effects of erythromycin on the PK of the 3 components of Ryeqo. Study MVT-601-55 is an interventional open label fixed single sequence cross-over study to assess whether a 6-hour dose separation is sufficient to mitigate absorption mediated increased exposure to relugolix and study MVT-601-057 is a 2-part study to assess the potential effect of relugolix on the PK of total dabigatran.

The updated RMP version (2.1) has also been submitted. As part of the application, the MAH also requests an extension of the market protection by one additional year." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023, 23.02.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.19. [VeraSeal - human fibrinogen / human thrombin - EMEA/H/C/004446/II/0027](#)

Instituto Grifols, S.A.

Rapporteur: Daniela Philadelphly, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur:

Amelia Cupelli

Scope: "Extension of indication to include treatment of children for VeraSeal, based on final results from study IG1405; this is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of VeraSeal as an adjunct to haemostasis during surgery in paediatric subjects. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.20. Voxzogo - vosoritide - Orphan - EMEA/H/C/005475/II/0006

BioMarin International Limited

Rapporteur: Martina Weise, PRAC Rapporteur: Zane Neikena

Scope: "Extension of indication to include treatment of children less than 2 years of age for Voxzogo, based on final results from the category 1 study BMN 111-206 and interim results from its open-label extension study 111-208. 111-206 is a phase 2 randomized, double-blind, placebo-controlled, multicentre study to assess the safety and efficacy of BMN 111 in infants and young children with achondroplasia. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Scenesse - afamelanotide - Orphan - EMEA/H/C/002548/II/0044

Clinuvel Europe Limited

Rapporteur: Janet Koenig, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication for the prevention of phototoxicity in adolescent patients (12 to under 18 years of age) with erythropoietic protoporphyria (EPP), based on the analysis of the safety and efficacy data available. As a consequence, sections 4.1, 4.2 and

4.4 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.4 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce a minor editorial correction to the PI.”

Letter by the applicant dated 30.08.2023 requesting an extension to the clock stop to respond to the RSI adopted in May 2023.

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the RSI adopted in May 2023.

5.2.2. [Valdoxan - agomelatine - EMEA/H/C/000915/II/0051](#)

Les Laboratoires Servier

Rapporteur: Eva Skovlund, PRAC Rapporteur: Pernille Harg

Scope: “Extension of indication to include new therapeutic indication in adolescents aged 12 to 17 years for the treatment of moderate to severe major depressive episodes, if depression is unresponsive to psychological therapy alone, for Valdoxan, further to the results of the phase 2 (CL2-20098-075) and phase 3 (CL3-20098-076) paediatric clinical studies included in the Paediatric Investigation Plan number EMEA-001181-PIP-11; As a consequence, the sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. The updated RMP version 25.1 has also been submitted.”

Request by the applicant for an extension to the clock stop to respond to the RSI adopted in June 2023.

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023, 26.01.2023.

The CHMP agreed to the request for an extension to the clock stop to respond to the RSI adopted in June 2023.

5.3. **Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006340

in vitro diagnostic device for laboratory use, intended for the qualitative detection of BRAF V600 mutations in DNA extracted from formalin-fixed, paraffin-embedded human tissue.

Scope: Request for supplementary information

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

6.3.2. in vitro diagnostic medical device - EMEA/H/D/006308

detection of HER2 antigen

Scope: Request for supplementary information

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

6.3.3. in vitro diagnostic medical device - EMEA/H/D/006310

immunohistochemical assay utilising an anti-PD-L1 monoclonal primary antibody

Scope: Request for supplementary information

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. elafibranor - Orphan - H0006231

Ipsen Pharma, Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. chikungunya virus, strain chikv Ir2006-opy1, live attenuated - H0005797

live-attenuated vaccine for prophylaxis against Chikungunya disease.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

The CHMP adopted the recommendations for PRIME eligibility.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website, in the PRIME homepage, under Outcome of eligibility section.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan

PTC Therapeutics International Limited

Rapporteur: Peter Mol, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Renewal of conditional marketing authorisation

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023.

See 2.3

An oral explanation was held on 12 September 2023. The presentation by the MAH focused on clinical and methodological aspects and in particular the results from study 041, results from a meta-analysis including studies 007, 020 and 041 as well as results from STRIDE registry (study 025).

The CHMP adopted a negative opinion by consensus, recommending not to renew the conditional marketing authorisation.

The CHMP assessment report was adopted.

The CHMP noted the public health communication.

9.1.2. Translarna - ataluren - EMEA/H/C/002720/II/0069, Orphan

PTC Therapeutics International Limited

Rapporteur: Peter Mol, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information following results from study PTC124-GD-041-DMD, listed as a specific obligation in the Annex II; This is a Phase 3 multicentre, randomised, double-blind, 18-month, placebo-controlled study, followed by a 18-month open label extension to confirm the efficacy and safety of ataluren in the treatment of ambulant patients with mnDMD aged 5 years or older. Annex II, and Annex IIB are updated to delete the SOB and to reflect the switch from conditional to full marketing authorisation.

The Package Leaflet is updated accordingly. The RMP version 11.0 has also been submitted. Minor corrections were done to align the PI with the latest QRD templates."

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023, 26.01.2023.

See 2.3

An oral explanation was held on 12 September 2023. The presentation by the MAH focused on clinical aspects and in particular the results from study 041.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the variation(s) to the terms of the marketing authorisation.

The CHMP assessment report was adopted.

The CHMP noted the public health communication.

9.1.3. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan

GlaxoSmithKline (Ireland) Limited

Rapporteur: Johanna Lähteenvuo, Co-Rapporteur: Carolina Prieto Fernandez, PRAC
Rapporteur: Ulla Wändel Liminga

Scope: Renewal of conditional marketing authorisation

Action: For adoption

Request for Supplementary Information adopted on 26.04.2023.

See 2.3

An oral explanation was held on 12 September 2023. The presentation by the MAH focused on clinical aspects.

The CHMP adopted a negative opinion by consensus, recommending not to renew the marketing authorisation.

The CHMP assessment report was adopted.

The CHMP noted the public health communication.

9.1.4. Ninlaro - ixazomib - EMEA/H/C/003844/II/0045, Orphan

Takeda Pharma A/S

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Submission of the Clinical Study Report (Addendum 2) for study C16019 listed as a Specific Obligation in the Annex II of the Product Information. This is a phase 3, randomized, double-blind, placebo-controlled study of single-agent oral ixazomib as maintenance therapy following autologous stem cell transplant (ASCT) for patients with newly diagnosed multiple myeloma. In addition, the MAH proposes to remove Ninlaro from the list of medicines subject to additional monitoring and to remove the black triangle from the SmPC. The Annex II and Package Leaflet are updated accordingly. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.5. Dovprela - pretomanid - EMEA/H/C/005167/II/0013, Orphan

Mylan IRE Healthcare Limited

Rapporteur: Filip Josephson

Scope: "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to change posology recommendations of linezolid, update frequency information of several adverse drug reactions as well as to update clinical efficacy information based on final results from ZeNix (NC007) study listed as a specific obligation (SOB/001) in the Annex II. ZeNix study is a phase III partially blinded, randomised trial assessing the safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary infection of either extensively drug resistant tuberculosis (XDR-TB), pre-XDR-TB or treatment intolerant or non-responsive multi-drug resistant tuberculosis (MDR-TB). The Package Leaflet (PL) is updated accordingly. As a result of this variation, the SmPC, Annex II and PL are also updated to reflect the completion of the specific obligation and the CHMP recommendation to grant a marketing authorisation no longer subject to specific obligations.

In addition, the MAH took the opportunity to implement editorial changes in the SmPC and PL and to update the list of local representatives in the PL.

In addition, the CHMP, having considered the application as set out in the appended assessment report and having reviewed the data submitted by the marketing authorisation holder including the evidence concerning compliance with specific obligations, is of the opinion that the risk-benefit balance of the above mentioned medicinal product remains favourable, that all specific obligations laid down in Annex II have been fulfilled and that comprehensive data supports a favourable benefit-risk balance of the above mentioned medicinal product. Therefore, pursuant to Article 14-a (8) of Regulation (EC) No 726/2004, the CHMP recommends by consensus the granting of a marketing authorisation in accordance with Article 14(1) of Regulation (EC) No 726/2004 for the above mentioned medicinal product for which the draft Summary of Product Characteristics is set out in Annex I."

Action: For adoption

Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.6. Ofev – nintedanib – EMEA/H/C/003821 LEG/006

Boehringer Ingelheim International GmbH

Rapporteur: Finbarr Leacy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Update on Post-Authorisation Measure LEG/006

Action: For information

The CHMP noted the update.

9.1.7. Brilique - ticagrelor - EMEA/H/C/001241/II/0061

AstraZeneca AB

Rapporteur: Patrick Vrijlandt

Scope: "Update of sections 4.2 and 4.4 of the SmPC in order to include a warning related to Single Antiplatelet Therapy (SAPT) in Patients with Acute Coronary Syndrome (ACS) who have undergone a Percutaneous Coronary Intervention (PCI) procedure and who have an increased risk of bleeding based on literature."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.8. Pandemic Influenza Vaccine H5N1 Baxter - Pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) – EMEA/H/C/001200

Resilience Biomanufacturing Ireland Limited

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Daniela Philadelphy, PRCA Rapporteur: Gabriele Maurer

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of the marketing authorisation.

9.1.9. Bimervax - sars-cov-2 virus, variants b.1.351-b.1.1.7, spike protein, receptor binding domain fusion heterodimer - EMEA/H/C/006058/II/0004

Hipra Human Health S.L.

Rapporteur: Beata Maria Jakline Ullrich

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and immunogenicity information after a fourth dose based on interim results from study HIPRA-HH-2) listed as a category 3 study in the RMP; this is A Phase IIb, Double-Blind, Randomised, Active -Controlled, Multicentre, Non-Inferiority Trial Followed By A Phase III, Single-Arm, Open-Label Trial To Assess Immunogenicity And Safety Of A Booster Vaccination With A Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-COV-2 In Adults Fully Vaccinated Against Covid-19 Followed By An Extension Period To Study A Fourth Dose Administration Of PHH-1V. The Package Leaflet is updated accordingly. In addition, the MAH submitted the full user consultation with target patient groups."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.10. Amyvid - Florbetapir (18F) - EMEA/H/C/002422/II/0044

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber

Scope: "Update of section 4.4 of the SmPC in order to remove the limitation regarding monitoring response to therapy based on available information in the scientific literature. The RMP version 4.1 has also been submitted. In addition, the MAH took the opportunity to update section 4.8 to the SmPC to align the clinical trial exposures with the RMP."

Action: For information

The CHMP noted the update.

9.1.11. Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/S/0004

SIGA Technologies Netherlands B.V.

Rapporteur: Jayne Crowe, PRAC Rapporteur: Martin Huber

Request for Supplementary Information adopted on 20.07.2023, 25.05.2023.

Action: For adoption

The Committee discussed the issues identified in this application relating to the RMP.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

9.1.12. Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/II/0006

SIGA Technologies Netherlands B.V.

PRAC Led; PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise

Scope: "Submission of substantial updates to the protocol of study SIGA-246-021 listed as a specific obligation in the Annex II of the Product Information in order to reflect the transfer of sponsorship from SIGA Technologies, Inc. to the NIH Division of Microbiology and Infection Disease protocol. This is a phase 4, observational field study to evaluate safety and clinical benefit in tecovirimat-treated patients following exposure to variola virus and clinical diagnosis of smallpox disease. The Annex II and the RMP submitted version 1.2 are updated accordingly."

Request for Supplementary Information adopted on 25.05.2023, 14.04.2023.

Action: For adoption

The Committee discussed the issues identified in this application relating to the RMP.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

9.1.13. Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0038, Orphan

Advanz Pharma Limited

Rapporteur: Carolina Prieto Fernandez

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to update clinical information based on final results from studies 747-302 and 747-401, listed as specific obligations in the Annex II, as well as results from real-world evidence (RWE) studies evaluating analyses of hepatic clinical outcomes. Study 747-302 is a confirmatory double-blind, randomised, placebo-controlled multicentre study investigating the clinical benefit associated with Ocaliva treatment in patients with PBC who are either unresponsive or intolerant to UDCA treatment based on clinical endpoints, while study 747-401 is a double-blind, randomised, placebo-controlled study evaluating the safety and pharmacokinetics of Ocaliva in patients with PBC and moderate to severe hepatic impairment. The Annex II and Package Leaflet are updated accordingly."

Update on the procedure

Action: For information

Request for Supplementary Information adopted on 30.03.2023.

The CHMP noted the update.

9.1.14. RoActemra - tocilizumab - EMEA/H/C/000955/II/0114

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension of indication to include treatment of new indication for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) for RoActemra, based on final results from the pivotal Phase III study WA29767 (focuSSced) entitled, "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis" and the supportive Phase II/III study WA27788 (faSScinat) entitled, "A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis".

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 28 of the RMP has also been submitted."

Withdrawal of extension of indication application

Action: For information

Request for Supplementary Information adopted on 26.04.2023, 15.12.2022.

See 2.3

An oral explanation was held on 11 September 2023. The presentation by the MAH focused on clinical aspects.

The CHMP noted the withdrawal of the extension of indication application.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

10.1.1. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065

Orexigen Therapeutics Ireland Limited

Referral Rapporteur: Thalia Marie Estrup Blicher, Referral Co-Rapporteur: Daniela Philadelphy

Scope: Start of procedure, appointment of rapporteurs, list of questions, timetable

Action: For adoption

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of Mysimba (naltrexone/bupropion), taking into account any consequences from the failure to comply with the obligations laid down in the marketing authorisation.

This review of all available data on the potential long-term cardiovascular risk and its impact on the benefit-risk balance of Mysimba in its approved indication was considered needed in view of the remaining concern and lack of adequate study plan to address the uncertainty about this risk.

In addition, the EC requests the Agency/CHMP to give its opinion, as soon as possible, as to whether temporary measures are necessary to ensure the safe and effective use of this medicinal product.

The CHMP appointed Thalia Marie Estrup Blicher as referral rapporteur and Daniela Philadelphy as referral co-rapporteur.

The CHMP agreed that no temporary measures should be taken at this stage.

The CHMP adopted a list of questions with a specific timetable.

Start of the procedure (CHMP): September 2023 CHMP

List of questions: 14 September 2023

Submission of responses: 23 October 2023

Re-start of the procedure: 14 November 2023

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 22 November 2023

Comments: 29 November 2023

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 05 December 2023

CHMP list of outstanding issues or CHMP opinion: December 2023 CHMP

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

10.5.1. Havrix - EMEA/H/A-30/1527

GlaxoSmithKline Biologicals

Referral Rapporteur: Maria Grazia Evandri, Referral Co-Rapporteur: Lyubina Racheva Todorova

Scope: Start of procedure, timetable

Action: For adoption

Harmonisation exercise for Havrix and associated names. Product Information harmonisation was triggered by the MAH.

The CHMP adopted the procedural timetable.

Start of procedure (CHMP): September 2023 CHMP

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 19 October 2023

Comments: 26 October 2023

Updated Rapporteur / co-rapporteur assessment reports circulated to CHMP: 31 October 2023

CHMP list of questions or CHMP opinion: November 2023 CHMP

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

September 2023 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of

such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Vote by proxy

Sol Ruiz gave a proxy to Maria Concepcion Prieto Yerro for the whole meeting.

14.1.2. CHMP membership

The Chair welcomed Paolo Gasparini as new alternate for Italy, Lyubina Racheva Todorova as new member and Gergana Lazarova as new alternate for Bulgaria.

14.1.3. CHMP co-opted membership

Discussion of area of expertise in light of the end of the mandate of Jan Mueller-Berghaus as co-opted member on 13 November 2023.

The current expertise of Jan-Mueller-Berghaus is 'Quality, safety and efficacy of biological medicinal products, including advanced therapies, and with specific emphasis on vaccines.'

Proposals should be sent.

Action: For adoption

The CHMP agreed on the area of expertise for the 5th co-opted member position as:

Quality, safety and efficacy of biological medicinal products with specific emphasis on vaccines, advanced therapies and biosimilars.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for September 2023

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

Agenda of the September 2023 PDCO plenary meeting

Action: For information

The CHMP noted the agenda.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sean Barry

Reports from BWP September 2023 meeting to CHMP for adoption:

- 14 reports on products in scientific advice and protocol assistance
- 18 reports on products in pre-authorisation procedures
- 8 reports on products in post-authorisation procedures

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 28-31 August 2023. Table of conclusions

Action: For information

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

The CHMP noted the update.

14.3.3. Election of Biosimilar Medicinal Product Working Party (BMWP) vice-chairperson

Chair: Rene Anour

Following the call for nominations launched in July, CHMP to elect the vice-chair from the candidates who submitted nominations.

Nomination(s) received

Action: For election

The CHMP elected Niklas Ekman (FI) as BMWP vice-chairperson.

14.3.4. Election of Quality Working Party (QWP) vice-chairperson

Chair: Blanka Hirschlerova

Following the call for nominations launched in July, CHMP to elect the vice-chair from the candidates who submitted nominations.

Nomination(s) received

Action: For election

The CHMP elected Nicholas Lee (IE) as QWP vice-chairperson.

14.3.5. Election of Biologics Working Party (BWP) vice-chairperson

Chair: Sean Barry

Following the call for nominations launched in July, CHMP to elect the vice-chair from the candidates who submitted nominations.

Nomination(s) received

Action: For election

The CHMP elected Francesca Luciani (IT) as BWP vice-chairperson.

14.3.6. Q&A on Model informed drug development (MIDD) in neonates

Methodology Working Party

Q&A on Model informed drug development (MIDD) in neonates

Action: For adoption

The CHMP adopted the Q&A.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

14.7.1. CHMP Work Plan 2023

Status update on the CHMP Work Plan for 2023.

Action: For information

The CHMP noted the update on the work plan 2023.

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

Q3-2023 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

The CHMP noted the report.

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the update.

15.1.2. Nitrosamine Q&A update

Action: For adoption

The CHMP adopted the updated Q&A on Nitrosamines.

List of Participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 11-14 September 2023 CHMP meeting, which was held in-person.

An asterisk (*) after the role, in the second column, signals that the member/alternate attended remotely. Additional experts participated in (part of) the meeting either in person or remotely.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Daniela Philadelphy	Member	Austria	No interests declared	
Christian Gartner	Alternate	Austria	No interests declared	
Christophe Focke	Member*	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Lyubina Racheva Todorova	Member	Bulgaria	No interests declared	
Gergana Lazarova	Alternate	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Tomas Radimersky	Member	Czechia	No interests declared	
Petr Vrbata	Alternate*	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No interests declared	
Aaron Sosa Mejia	Alternate	Denmark	No participation in final deliberations and voting on:	insulin icodex - EMEA/H/C/005978
Alar Irs	Member*	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member*	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Robert Porszasz	Member	Hungary	No interests declared	
Beata Maria Jakline Ullrich	Alternate	Hungary	No interests declared	
Hjalti Kristinsson	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Finbarr Leacy	Alternate	Ireland	No interests declared	
Paolo Gasparini	Member*	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Vilma Petrikaite	Member	Lithuania	No interests declared	
Larisa Gorobets	Alternate*	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
Alexandra Branchu	Alternate	Luxembourg	No participation in discussion, final deliberations and voting on:	Fexinidazole Winthrop - fexinidazole - EMEA/H/W/002320 /II/0016
John Joseph Borg	Member	Malta	No interests declared	
Peter Mol	Member	Netherlands	No interests declared	
Patrick Vrijlandt	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member*	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Frantisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate*	Slovakia	No interests declared	
Andreja Kranjc	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Carolina Prieto Fernandez	Alternate*	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Bruno Delafont	Co-opted member	France	No participation in discussion, final deliberations and voting on:	Brilique - ticagrelor EMEA/H/C/001241 /II/0061 Capiwasertib - EMEA/H/C/006017
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member*	Spain	No interests declared	
Vincent Gazin	Expert	France	No interests declared	
Céline Chu	Expert	France	No interests declared	
Sylvie Benchetrit	Expert	France	No interests declared	
Nathalie Morgensztejn	Expert	France	No interests declared	
Camille De Kervasdoue	Expert	France	No interests declared	
Anissa Benlazar	Expert	France	No interests declared	
Karin Fjorden	Expert	Sweden	No participation in final deliberations and voting on:	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0121 EMEA/H/C/003820/II/0135 EMEA/H/C/003820/II/0138
Maria Winqvist	Expert	Sweden	No interests declared	
Jenny Jönsson	Expert	Sweden	No participation in final deliberations and voting on:	Rubraca - rucaparib - EMEA/H/C/004272/II/0036 Opdivo - nivolumab - EMEA/H/C/003985/X/0132
			No participation in discussion, final deliberations and voting on:	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0121 EMEA/H/C/003820/II/0135 EMEA/H/C/003820/II/0138
Daiana Vasilcanu	Expert	Sweden	No interests declared	
Camilla Birgitta Göktürk	Expert	Sweden	No interests declared	
Charlotte Welsh	Expert	Sweden	No restrictions applicable to this meeting	
Inga Soveri	Expert	Sweden	No restrictions applicable to this meeting	
Charlotte Anderberg	Expert	Sweden	No interests declared	
Sara Camilleri	Expert	Malta	No interests declared	
Matthew Camilleri	Expert	Malta	No interests declared	
Luca Fancsalszky	Expert	Hungary	No interests declared	
Maria Paile-Hyvärinen	Expert	Finland	No interests declared	
John Aspegren	Expert	Finland	No restrictions applicable to this meeting	
Maija Tarkkanen	Expert	Finland	No interests declared	
Bojana Divkovic	Expert	Austria	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Christine Schilhart-Wallisch	Expert	Austria	No interests declared	
Markus Tomek	Expert	Austria	No interests declared	
Kine Marita Knudsen Sand	Expert	Norway	No interests declared	
Sinead Harrington	Expert	Ireland	No interests declared	
Benita Cullen	Expert	Ireland	No interests declared	
Catherine Byrne	Expert	Ireland	No interests declared	
Agnieszka Przybyszewska	Expert	Ireland	No interests declared	
Larissa Higgins	Expert	Ireland	No interests declared	
Caoimhin Concannon	Expert	Ireland	No interests declared	
Liam McDonough	Expert	Ireland	No interests declared	
Kairi Rooma	Expert	Estonia	No interests declared	
Jana Klimasová	Expert	Slovakia	No restrictions applicable to this meeting	
Anna Kubandová	Expert	Slovakia	No interests declared	
Eva Malikova	Expert	Slovakia	No interests declared	
Jana Schweigertová	Expert	Slovakia	No interests declared	
Peter Šišovský	Expert	Slovakia	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Odoardo Maria Olimpieri	Expert	Italy	No interests declared	
Antonella Isgrò	Expert	Italy	No interests declared	
Cristina Migali	Expert	Italy	No interests declared	
Federico De Angelis	Expert	Italy	No interests declared	
Maria Di Marzo	Expert	Italy	No interests declared	
Gabriella Passacquale	Expert	Italy	No interests declared	
Cinzia Ciceroni	Expert	Italy	No interests declared	
Danila Renzo	Expert	Italy	No interests declared	
Valentina Conti	Expert	Italy	No interests declared	
Marta Lafuente Gonzalez	Expert	Spain	No interests declared	
Macarena Gajardo Alvarez	Expert	Spain	No interests declared	
Beatriz Gutiérrez Eugenio	Expert	Spain	No interests declared	
Teresa Delicado Llazer	Expert	Spain	No interests declared	
Daniel Fernández Soto	Expert	Spain	No interests declared	
Laura Gómez	Expert	Spain	No interests declared	
Pablo de Felipe	Expert	Spain	No interests declared	
Macarena Rodriguez Mendizabal	Expert	Spain	No interests declared	
Ana Martín Leal	Expert	Spain	No interests declared	
Loes den Otter	Expert	Netherlands	No interests declared	
Hinke Johanna van der Woude	Expert	Netherlands	No interests declared	
Monique van Raamsdonk	Expert	Netherlands	No interests declared	
Karolina Kwiatek	Expert	Netherlands	No interests declared	
Marika van Leeuwen-Artz	Expert	Netherlands	No interests declared	
Susanne van Burg-Bouwman	Expert	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Viktoriia Starokozhko	Expert	Netherlands	No restrictions applicable to this meeting	
Carlijn Litjens	Expert	Netherlands	No interests declared	
Maaïke Cronenberg	Expert	Netherlands	No restrictions applicable to this meeting	
Rou-Afza Gunput	Expert	Netherlands	No interests declared	
André Elferink	Expert	Netherlands	No interests declared	
Lieke Sandberg-Smits	Expert	Netherlands	No interests declared	
Sabine van der Putten - de Brouwer	Expert	Netherlands	No restrictions applicable to this meeting	
Derk Reinders	Expert	Netherlands	No interests declared	
Bettina Klug	Expert	Germany	No interests declared	
Lukas Malte Aguirre Davila	Expert	Germany	No interests declared	
Juliane Rau	Expert	Germany	No interests declared	
Atila Sebe	Expert	Germany	No interests declared	
Michal Zwiewka	Expert	Germany	No interests declared	
Johanna Kuhlmann-Gottke	Expert	Germany	No restrictions applicable to this meeting	
Beate Mosl	Expert	Germany	No interests declared	
Linda Marchioro	Expert	Germany	No interests declared	
Samira Alina Marx	Expert	Germany	No interests declared	
Susanne Mueller-Egert	Expert	Germany	No interests declared	
Hilke Zander	Expert	Germany	No interests declared	
Jörg Engelbergs	Expert	Germany	No interests declared	
Sara Tognarelli	Expert	Germany	No restrictions applicable to this meeting	
Christian Merz	Expert	Germany	No restrictions applicable to this meeting	
Yasmin Molter	Expert	Germany	No interests declared	
Edwige Haelterman	Expert	Belgium	No interests declared	
Violette Dirix	Expert	Belgium	No interests declared	
Inne Crevecoeur	Expert	Belgium	No participation in discussion, final deliberations and voting on:	Keytruda - pembrolizumab - EMEA/H/C/003820 /II/0121 EMEA/H/C/003820 /II/0135 EMEA/H/C/003820 /II/0138 arpraziquantel - Article 58 - EMEA/H/W/004252
Marta Romano	Expert	Belgium	No interests declared	
Filip Van Nuffel	Expert	Belgium	No interests declared	
Nicolas Nyssen	Expert	Belgium	No interests declared	
Valérie Lescrainier	Expert	Belgium	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Franziska Wolter	Expert	Germany	No interests declared	
Febrin Hennemann	Expert	Germany	No interests declared	
Sofia Kapanadze	Expert	Germany	No restrictions applicable to this meeting	
Ingrid Ackermann	Expert	Germany	No interests declared	
Georgios Aislaitner	Expert	Germany	No interests declared	
Ulrike Hermes	Expert	Germany	No interests declared	
Martin Mengel	Expert	Germany	No interests declared	
Bruna Dekic	Expert	Germany	No interests declared	
Norbert Benda	Expert	Germany	No interests declared	
Anne-Marie Dalseg	Expert	Denmark	No interests declared	
Anne Hasle Buur	Expert	Denmark	No interests declared	
Line Præst Lauridsen	Expert	Denmark	No restrictions applicable to this meeting	
Susanne Høpner Rasmussen	Expert	Denmark	No interests declared	
Claus Stage	Expert	Denmark	No restrictions applicable to this meeting	
Emilie Birch Kristensen	Expert	Denmark	No restrictions applicable to this meeting	
Deirdre Mannion	Expert	Denmark	No restrictions applicable to this meeting	
Thadeus Bao Quan Nguyen	Expert	Denmark	No interests declared	
Boje Kvorning Pires Ehmsen	Expert	Denmark	No interests declared	
Torsten Holm Nielsen	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Kinga Nowicka-Matus	Expert	Denmark	No interests declared	
Ebru Karakoc Madsen	Expert	Denmark	No interests declared	
Sine Buhl Næss-Schmidt	Expert	Denmark	No restrictions applicable to this meeting	
Ann-Cathrine Bach Dunvald	Expert	Denmark	No interests declared	
Pierre Demolis	Expert	France	No interests declared	
Brigitte Schwarzer-Daum	Expert	Austria	No interests declared	
Jens Reinhardt	Expert	Germany	No interests declared	
Karri Penttila	Expert	Finland	No interests declared	
Kristian Wennmalm	Expert	Sweden	No interests declared	
Flora Musuamba Tshinanu	Expert	Belgium	No restrictions applicable to this meeting	
Andrea Laslop	Expert	Austria	No interests declared	
Rosalía Ruano Camps	Expert	Spain	No interests declared	
Nina Pettersen Hessvik	Expert	Norway	No interests declared	
Maria José Aguilera	Expert	Spain	No interests declared	
Elisabeth Fuerst	Expert	Austria	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Gwladys Naissant	Expert	France	No participation in discussion, final deliberations and voting on:	Fexinidazole Winthrop - fexinidazole - EMEA/H/W/002320 /II/0016
Harald Bernsteiner	Expert	Austria	No interests declared	
Sabrina Jenull	Expert	Austria	No restrictions applicable to this meeting	
Franz Rieder-Rommer	Expert	Austria	No restrictions applicable to this meeting	
Viktor András Billes	Expert	Hungary	No interests declared	
Beáta Szabady	Expert	Hungary	No interests declared	
Sara Galluzzo	Expert	Italy	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	
Charlotte Hejl	Expert	Denmark	No restrictions applicable to this meeting	
Louisa Braun Exner	Expert	Denmark	No interests declared	
Kristina Bech Jensen	Expert	Denmark	No interests declared	
Kristin Skougaard	Expert	Denmark	No interests declared	
Serge Bakchine	Expert	Expert recommended by EMA	No restrictions against giving the SAG report on Translarna	
Lothar Bergmann	Expert	Expert recommended by EMA	No restrictions against giving the SAG report on Blenrep	
Paula Contreras Alarcón	Expert	Spain	No restrictions applicable to this meeting	
Cristel Loeb	Expert	Netherlands	No interests declared	
Gerlienke Geurts-Voerman	Expert	Netherlands	No interests declared	
Friederike Feldmann	Expert	Germany	No interests declared	
Iva Gottsteinová	Expert	Czechia	No interests declared	
Gianluca Miglio	Expert	Italy	No restrictions applicable to this meeting	
Charlotte Geluk	Expert	Swissmedic	No interests declared	

A representative from the European Commission attended the meeting.

Meeting run with the help of EMA staff.

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)


The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



14 November 2023
EMA/CHMP/417017/2023

Annex to 11-14 September 2023 CHMP Minutes

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES	4
A.1. ELIGIBILITY REQUESTS.....	4
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications	4
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION	4
B. POST-AUTHORISATION PROCEDURES OUTCOMES	4
B.1. Annual re-assessment outcomes	4
B.1.1. Annual reassessment for products authorised under exceptional circumstances	4
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal	4
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	4
B.2.3. Renewals of Conditional Marketing Authorisations	6
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES.....	7
B.4. EPARs / WPARs	10
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	11
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	11
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	19
B.5.3. CHMP-PRAC assessed procedures	42
B.5.4. PRAC assessed procedures.....	50
B.5.5. CHMP-CAT assessed procedures	57
B.5.6. CHMP-PRAC-CAT assessed procedures	59
B.5.7. PRAC assessed ATMP procedures	60
B.5.8. Unclassified procedures and worksharing procedures of type I variations	60
B.5.9. Information on withdrawn type II variation / WS procedure	63
B.5.10. Information on type II variation / WS procedure with revised timetable	63
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION	63
B.6.1. Start of procedure for New Applications: timetables for information	63
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information	64



B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information.....	64
B.6.4. Annual Re-assessments: timetables for adoption	66
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed	66
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	66
B.6.7. Type II Variations scope of the Variations: Extension of indication	66
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	66
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	68
B.6.10. CHMP-PRAC assessed procedures.....	72
B.6.11. PRAC assessed procedures	74
B.6.12. CHMP-CAT assessed procedures	76
B.6.13. CHMP-PRAC-CAT assessed procedures.....	77
B.6.14. PRAC assessed ATMP procedures	78
B.6.15. Unclassified procedures and worksharing procedures of type I variations	78
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY.....	79
B.7.1. Yearly Line listing for Type I and II variations.....	79
B.7.2. Monthly Line listing for Type I variations.....	79
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)	79
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)	79
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)	79
B.7.6. Notifications of Type I Variations (MMD only)	79
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)	79
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	79
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES	79
E.1. PMF Certification Dossiers:.....	80
E.1.1. Annual Update.....	80
E.1.2. Variations:	80
E.1.3. Initial PMF Certification:.....	80
E.2. Time Tables – starting & ongoing procedures: For information	80
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver	80
G. ANNEX G.....	80
G.1. Final Scientific Advice (Reports and Scientific Advice letters):	80
G.2. PRIME.....	80
G.2.1. List of procedures concluding at 11-14 September 2023 CHMP plenary:	80
G.2.2. List of procedures starting in September 2023 for October 2023 CHMP adoption of outcomes	81

H. ANNEX H - Product Shared Mailboxes – e-mail address..... 81

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for September 2023: For adoption	Adopted
--	---------

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for September 2023: For adoption	Adopted
--	---------

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

EVKEEZA - evinacumab - EMEA/H/C/005449/S/0010 Ultragenyx Germany GmbH, Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Mari Thorn	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
--	---

Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/S/0004 SIGA Technologies Netherlands B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 14.09.2023, 20.07.2023, 25.05.2023.	Request for supplementary information adopted with a specific timetable. See 9.1
--	---

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

AJOVY - fremanezumab - EMEA/H/C/004833/R/0044 TEVA GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Mol, PRAC Rapporteur:	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available
---	---

Kirsti Villikka	information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
<p>GHRYVELIN - macimorelin - EMEA/H/C/004660/R/0020</p> <p>Atnahs Pharma Netherlands B.V., Rapporteur: Martina Weise, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Liana Gross-Martirosyan</p> <p>Request for Supplementary Information adopted on 14.09.2023.</p>	Request for supplementary information adopted with a specific timetable.
<p>Idacio - adalimumab - EMEA/H/C/004475/R/0022</p> <p>Fresenius Kabi Deutschland GmbH, Rapporteur: Peter Mol, Co-Rapporteur: Vilma Petrikaite, PRAC Rapporteur: Mari Thorn</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Miglustat Dipharma - miglustat - EMEA/H/C/004904/R/0019</p> <p>DIPHARMA Arzneimittel GmbH, Generic, Generic of Zavesca, Rapporteur: Frantisek Drafi, PRAC Rapporteur: Mari Thorn</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Mulpleo - lusutrombopag - EMEA/H/C/004720/R/0018</p> <p>Shionogi B.V., Rapporteur: Daniela Philadelphia, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Mari Thorn</p> <p>Request for Supplementary Information adopted on 14.09.2023.</p>	Request for supplementary information adopted with a specific timetable.
<p>Pelmeg - pegfilgrastim - EMEA/H/C/004700/R/0025</p> <p>Mundipharma Corporation (Ireland) Limited, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Christian Gartner, PRAC Rapporteur: Menno van der Elst</p> <p>Request for Supplementary Information adopted on 22.06.2023.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Rizmoic - naldemedine - EMEA/H/C/004256/R/0023</p> <p>Shionogi B.V., Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Rhea Fitzgerald</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can</p>

	be granted with unlimited validity.
<p>Silodosin Recordati - silodosin - EMEA/H/C/004964/R/0012 Recordati Ireland Ltd, Generic, Generic of Urorec, Rapporteur: Margareta Bego, PRAC Rapporteur: Valentina Di Giovanni Request for Supplementary Information adopted on 20.07.2023.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Skyrizi - risankizumab - EMEA/H/C/004759/R/0039 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Finbarr Leacy, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 14.09.2023.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Zirabev - bevacizumab - EMEA/H/C/004697/R/0029 Pfizer Europe MA EEIG, Rapporteur: Eva Skovlund, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>B.2.3. Renewals of Conditional Marketing Authorisations</p>	
<p>Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan GlaxoSmithKline (Ireland) Limited, Rapporteur: Johanna Lähtenvuo, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 22.06.2023, 26.04.2023.</p>	<p>The CHMP adopted a negative opinion by consensus, recommending not to renew the marketing authorisation.</p> <p>See 2.3 and 9.1</p>
<p>Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/R/0035 Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Peter Mol, PRAC Rapporteur: Ana Sofia Diniz Martins</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p>
<p>LUMYKRAS - sotorasib - EMEA/H/C/005522/R/0012 Amgen Europe B.V., Rapporteur: Alexandre Moreau, Co-Rapporteur: Johanna Lähtenvuo, PRAC Rapporteur: Marie Louise Schougaard</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can</p>

Christiansen	be granted. The Marketing Authorisation remains conditional.
Ocaliva - obeticholic acid - EMEA/H/C/004093/R/0042, Orphan Advanz Pharma Limited, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Liana Gross-Martirosyan	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan PTC Therapeutics International Limited, Rapporteur: Peter Mol, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 25.05.2023.	The CHMP adopted a negative opinion by consensus, recommending not to renew the marketing authorisation. See 2.3 and 9.1
Zynlonta - loncastuximab tesirine - EMEA/H/C/005685/R/0009 Swedish Orphan Biovitrum AB (publ), Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Post-authorisation safety studies

PRAC recommendations on PASS results adopted at the PRAC meeting held on 28-31 August 2023 PRAC:

Daxas – EMEA-H-C-PSR-S-0041 (roflumilast) PRAC Rapporteur: Monica Martinez Redondo, Scope: Final study report for a long-term post-marketing observational study of the safety of roflumilast PRAC recommendation to CHMP Action: For adoption	Adopted
---	---------

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its September 2023 meeting:

EMA/H/C/PSUSA/0000010/202212

(abacavir)

CAPS:

Ziagen (EMA/H/C/000252) (abacavir), ViiV Healthcare B.V., Rapporteur: Jean-Michel Race

NAPS:

NAPs - EU

PRAC Rapporteur: Nathalie Gault,

"01/01/2020 To: 31/12/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of section 4.4 of the SmPC to add a warning/precaution regarding cardiovascular events. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/0000011/202212

(abacavir / lamivudine)

CAPS:

Kivexa (EMA/H/C/000581) (lamivudine / abacavir), ViiV Healthcare B.V., Rapporteur: Jean-Michel Race

NAPS:

NAPs - EU

PRAC Rapporteur: Nathalie Gault,

"01/01/2020 To: 31/12/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of section 4.4 of the SmPC to add a warning/precaution regarding cardiovascular events. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00003144/202212

(abacavir / lamivudine / zidovudine)

CAPS:

Trizivir (EMA/H/C/000338) (lamivudine / abacavir / zidovudine), ViiV Healthcare B.V., Rapporteur: Alexandre Moreau

NAPS:

NAPs - EU

PRAC Rapporteur: Nathalie Gault,

"01/01/2020 To: 31/12/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of section 4.4 of the SmPC to add a warning/precaution regarding cardiovascular events. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010075/202301

(dolutegravir, dolutegravir / abacavir / lamivudine, dolutegravir / lamivudine)

CAPS:

Dovato (EMA/H/C/004909) (dolutegravir / lamivudine), ViiV Healthcare B.V., Rapporteur: Filip Josephson

Tivicay (EMA/H/C/002753) (dolutegravir), ViiV Healthcare B.V., Rapporteur: Filip Josephson

Triumeq (EMA/H/C/002754) (dolutegravir / abacavir / lamivudine), ViiV Healthcare B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber, "17/01/2021 To: 16/01/2023"

For Dovato and Tivicay, the CHMP, having considered in accordance with Article 28(4) of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the maintenance of the terms of the marketing authorisation(s).

For Triumeq, the CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation concerning the following changes:

Update of section 4.4 of the SmPC to amend a warning/precaution regarding the risk of cardiovascular events for Triumeq, as an abacavir containing product, in view of the available data coming from the literature regarding abacavir and its possible relation with cardiovascular events (notably myocardial infarction) in patients treated with abacavir. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010903/202301

(brexucabtagene autoleucel)

CAPS:

Tecartus (EMA/H/C/005102) (brexucabtagene autoleucel), Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "22/07/2022 To: 22/01/2023"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add infusion related reaction with a frequency common. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010984/202212

((1r,2s,5s)-n-((1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl)-6,6-dimethyl-3-[3-methyl-n-(trifluoroacetyl)-l-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir (Paxlovid))

CAPS:

Paxlovid (EMA/H/C/005973) (nirmatrelvir / ritonavir), Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "01/07/2022 To: 31/12/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s):

Update of section 4 of the package leaflet to amend the current information regarding dysgeusia. In addition, the MAH took the opportunity to perform some editorial changes.

EMA/H/C/PSUSA/00010994/202301

(relugolix)

CAPS:

Orgovyx (EMA/H/C/005353) (relugolix), Accord Healthcare S.L.U., Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "07/07/2022 To: 07/01/2023"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following changes:

Update of section 4.8 the SmPC to add the adverse reactions urticaria and angioedema with a frequency of uncommon. The package leaflet is updated accordingly.

B.4. EPARs / WPARs

LYFNUA - gefapixant - EMA/H/C/005476

Merck Sharp & Dohme B.V., treatment of refractory or unexplained chronic cough, New active substance (Article 8(3) of Directive No 2001/83/EC)

WPAR

For information only. Comments can be sent to the PL in case necessary.

SKYCovion (WD) - gbp510 - EMA/H/C/005998

SK Chemicals GmbH, prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older, New active substance (Article 8(3) of Directive No 2001/83/EC)

WPAR

For information only. Comments can be sent to the PL in case necessary.

Vivjoa (WD) - oteseconazole - EMA/H/C/005682

Gedeon Richter Plc., treatment and prevention of recurrent vulvovaginal candidiasis (RVVC) including the acute episodes of RVVC in adult women
New active substance (Article 8(3) of Directive

For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Accofil - filgrastim - EMA/H/C/003956/II/0057/G Accord Healthcare S.L.U., Rapporteur: Outi Mäki-Ikola Opinion adopted on 14.09.2023.	Positive Opinion adopted by consensus on 14.09.2023.
Adtralza - tralokinumab - EMA/H/C/005255/II/0010 LEO Pharma A/S, Rapporteur: Jayne Crowe Request for Supplementary Information adopted on 31.08.2023.	Request for supplementary information adopted with a specific timetable.
Allymsys - bevacizumab - EMA/H/C/005286/II/0022 Mabxience Research SL, Rapporteur: Christian Gartner Opinion adopted on 14.09.2023. Request for Supplementary Information adopted on 29.06.2023.	Positive Opinion adopted by consensus on 14.09.2023.
Benlysta - belimumab - EMA/H/C/002015/II/0115/G GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder Opinion adopted on 07.09.2023.	Positive Opinion adopted by consensus on 07.09.2023.
Byooviz - ranibizumab - EMA/H/C/005545/II/0012/G Samsung Bioepis NL B.V., Rapporteur: Christian Gartner Request for Supplementary Information adopted on 31.08.2023.	Request for supplementary information adopted with a specific timetable.
Cinacalcet Mylan - cinacalcet - EMA/H/C/004014/II/0023/G Mylan Pharmaceuticals Limited, Generic, Generic of Mimpara, Rapporteur: Tomas Radimersky Opinion adopted on 14.09.2023.	Positive Opinion adopted by consensus on 14.09.2023.
COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) -	Positive Opinion adopted by consensus on 30.08.2023.

EMA/H/C/005735/II/0183

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson
Opinion adopted on 30.08.2023.

**Darunavir Mylan - darunavir -
EMA/H/C/004068/II/0021**

Mylan Pharmaceuticals Limited, Generic,
Generic of Prezista, Rapporteur: John Joseph
Borg
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Dukoral - cholera vaccine (inactivated,
oral) - EMA/H/C/000476/II/0071**

Valneva Sweden AB, Rapporteur: Kristina
Dunder
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Efavirenz/Emtricitabine/Tenofovir
disoproxil Mylan - efavirenz / emtricitabine
/ tenofovir disoproxil -
EMA/H/C/004240/II/0025**

Mylan Pharmaceuticals Limited, Generic,
Generic of Atripla (SRD), Rapporteur: Bruno
Sepodes
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on
31.08.2023.

**Elaprase - idursulfase -
EMA/H/C/000700/II/0109**

Takeda Pharmaceuticals International AG
Ireland Branch, Rapporteur: Patrick Vrijlandt
Request for Supplementary Information adopted
on 31.08.2023, 25.05.2023.

Request for supplementary information adopted
with a specific timetable.

**Entyvio - vedolizumab -
EMA/H/C/002782/II/0079/G**

Takeda Pharma A/S, Rapporteur: Paolo
Gasparini
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Flucelvax Tetra - influenza vaccine (surface
antigen, inactivated, prepared in cell
cultures) - EMA/H/C/004814/II/0039**

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Gazyvaro - obinutuzumab -
EMA/H/C/002799/II/0053/G, Orphan**

Roche Registration GmbH, Rapporteur: Aaron
Sosa Mejia

Positive Opinion adopted by consensus on
07.09.2023.

Opinion adopted on 07.09.2023.
Request for Supplementary Information adopted
on 22.06.2023.

**Giapreza - angiotensin II -
EMA/H/C/004930/II/0024**

Paion Deutschland GmbH, Rapporteur: Maria
Concepcion Prieto Yerro
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on
31.08.2023.

**GONAL-f - follitropin alfa -
EMA/H/C/000071/II/0163/G**

Merck Europe B.V., Rapporteur: Patrick Vrijlandt
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Imraldi - adalimumab -
EMA/H/C/004279/II/0066/G**

Samsung Bioepis NL B.V., Rapporteur: Outi
Mäki-Ikola
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Ivabradine Accord - ivabradine -
EMA/H/C/004241/II/0016/G**

Accord Healthcare S.L.U., Generic, Generic of
Procoralan, Rapporteur: Anastasia Mountaki
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted
on 29.06.2023, 08.12.2022.

Positive Opinion adopted by consensus on
31.08.2023.

**Lenalidomide Mylan - lenalidomide -
EMA/H/C/005306/II/0014**

Mylan Ireland Limited, Generic, Generic of
Revlimid, Rapporteur: Anastasia Mountaki
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on
31.08.2023.

**Lokelma - sodium zirconium cyclosilicate -
EMA/H/C/004029/II/0032**

AstraZeneca AB, Rapporteur: Larisa Gorobets
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Mounjaro - tirzepatide -
EMA/H/C/005620/II/0004/G**

Eli Lilly Nederland B.V., Rapporteur: Martina
Weise
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted
on 29.06.2023, 20.04.2023.

Positive Opinion adopted by consensus on
31.08.2023.

**Mounjaro - tirzepatide -
EMA/H/C/005620/II/0006/G**

Eli Lilly Nederland B.V., Rapporteur: Martina

Positive Opinion adopted by consensus on
31.08.2023.

Weise

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 13.07.2023, 12.05.2023.

Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0029/G, Orphan
Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on 31.08.2023.

Nepexto - etanercept - EMEA/H/C/004711/II/0023
Biosimilar Collaborations Ireland Limited,
Rapporteur: Martina Weise
Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

Nepexto - etanercept - EMEA/H/C/004711/II/0024
Biosimilar Collaborations Ireland Limited,
Rapporteur: Martina Weise
Request for Supplementary Information adopted on 07.09.2023.

Request for supplementary information adopted with a specific timetable.

Opzelura - ruxolitinib - EMEA/H/C/005843/II/0002/G
Incyte Biosciences Distribution B.V.,
Rapporteur: Peter Mol
Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

Oyavas - bevacizumab - EMEA/H/C/005556/II/0022
STADA Arzneimittel AG, Duplicate, Duplicate of Alymsys, Rapporteur: Christian Gartner
Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted on 06.07.2023.

Positive Opinion adopted by consensus on 14.09.2023.

Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0115
Zr Pharma& GmbH, Rapporteur: Filip Josephson
Request for Supplementary Information adopted on 14.09.2023.

Request for supplementary information adopted with a specific timetable.

Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/II/0087/G
Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher
Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

POTELIGEO - mogamulizumab -

Positive Opinion adopted by consensus on

<p>EMA/H/C/004232/II/0020, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Peter Mol Opinion adopted on 31.08.2023. Request for Supplementary Information adopted on 22.06.2023, 14.04.2023.</p>	31.08.2023.
<p>Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - EMA/H/C/001104/II/0215/G Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 31.08.2023.</p>	Request for supplementary information adopted with a specific timetable.
<p>Ranivisio - ranibizumab - EMA/H/C/005019/II/0008 Midas Pharma GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 31.08.2023.</p>	Positive Opinion adopted by consensus on 31.08.2023.
<p>Remicade - infliximab - EMA/H/C/000240/II/0242 Janssen Biologics B.V., Rapporteur: Kristina Dunder Opinion adopted on 31.08.2023.</p>	Positive Opinion adopted by consensus on 31.08.2023.
<p>Remsima - infliximab - EMA/H/C/002576/II/0131/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Opinion adopted on 31.08.2023.</p>	Positive Opinion adopted by consensus on 31.08.2023.
<p>Respreeza - human alpha1-proteinase inhibitor - EMA/H/C/002739/II/0071 CSL Behring GmbH, Rapporteur: Kristina Dunder Opinion adopted on 14.09.2023.</p>	Positive Opinion adopted by consensus on 14.09.2023.
<p>Simponi - golimumab - EMA/H/C/000992/II/0115 Janssen Biologics B.V., Rapporteur: Kristina Dunder Opinion adopted on 31.08.2023.</p>	Positive Opinion adopted by consensus on 31.08.2023.
<p>Skyrizi - risankizumab - EMA/H/C/004759/II/0042 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Finbarr Leacy Opinion adopted on 14.09.2023.</p>	Positive Opinion adopted by consensus on 14.09.2023.
<p>Soliris - eculizumab - EMA/H/C/000791/II/0128/G, Orphan</p>	Request for supplementary information adopted with a specific timetable.

Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez
Request for Supplementary Information adopted on 31.08.2023.

Spikevax - Covid-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0094/G Positive Opinion adopted by consensus on 31.08.2023.
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 16.03.2023.

Spikevax - Covid-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0100/G Positive Opinion adopted by consensus on 31.08.2023.
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 15.06.2023.

Spikevax - covid-19 mrna vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0111/G Positive Opinion adopted by consensus on 14.09.2023.
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 14.09.2023.

TOBI Podhaler - tobramycin - EMEA/H/C/002155/II/0057/G Positive Opinion adopted by consensus on 31.08.2023.
Viartis Healthcare Limited, Rapporteur: Patrick Vrijlandt
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 15.06.2023.

TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0023/G Positive Opinion adopted by consensus on 31.08.2023.
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 08.06.2023.

TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0024/G Positive Opinion adopted by consensus on 31.08.2023.
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 08.06.2023.

<p>Ultomiris - ravulizumab - EMA/H/C/004954/II/0039</p> <p>Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez</p> <p>Opinion adopted on 31.08.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>
<p>Uptravi - selexipag - EMA/H/C/003774/II/0039</p> <p>Janssen-Cilag International N.V., Rapporteur: Martina Weise</p> <p>Request for Supplementary Information adopted on 07.09.2023.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Vaxchora - cholera vaccine, oral, live - EMA/H/C/003876/II/0020</p> <p>Emergent Netherlands B.V., Rapporteur: Ingrid Wang</p> <p>Opinion adopted on 14.09.2023.</p> <p>Request for Supplementary Information adopted on 20.07.2023.</p>	<p>Positive Opinion adopted by consensus on 14.09.2023.</p>
<p>VEYVONDI - vonicog alfa - EMA/H/C/004454/II/0031</p> <p>Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 31.08.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>
<p>Vocabria - cabotegravir - EMA/H/C/004976/II/0016/G</p> <p>ViiV Healthcare B.V., Rapporteur: Jean-Michel Race</p> <p>Opinion adopted on 31.08.2023.</p> <p>Request for Supplementary Information adopted on 29.06.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>
<p>Xeljanz - tofacitinib - EMA/H/C/004214/II/0053/G</p> <p>Pfizer Europe MA EEIG, Rapporteur: Paolo Gasparini</p> <p>Request for Supplementary Information adopted on 31.08.2023.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Zerbaxa - ceftolozane / tazobactam - EMA/H/C/003772/II/0041</p> <p>Merck Sharp & Dohme B.V., Rapporteur: Ingrid Wang</p> <p>Opinion adopted on 07.09.2023.</p> <p>Request for Supplementary Information adopted on 20.07.2023.</p>	<p>Positive Opinion adopted by consensus on 07.09.2023.</p>
<p>Zercepac - trastuzumab - EMA/H/C/005209/II/0021</p> <p>Accord Healthcare S.L.U., Rapporteur: Sol Ruiz</p> <p>Opinion adopted on 31.08.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>

Request for Supplementary Information adopted on 01.12.2022.

WS2457/G
Riltrava Aerosphere-
EMA/H/C/005311/WS2457/0005/G

Positive Opinion adopted by consensus on 31.08.2023.

Trixeo Aerosphere-
EMA/H/C/004983/WS2457/0012/G

AstraZeneca AB, Lead Rapporteur: Finbarr Leacy

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 12.05.2023.

WS2507
Bondronat-
EMA/H/C/000101/WS2507/0092

Request for supplementary information adopted with a specific timetable.

Bonviva-
EMA/H/C/000501/WS2507/0076

Atrahs Pharma Netherlands B.V., Lead Rapporteur: Thalia Marie Estrup Blicher

Request for Supplementary Information adopted on 07.09.2023, 06.07.2023.

WS2522/G
Dengue Tetravalent Vaccine (Live, Attenuated) Takeda-
EMA/H/W/005362/WS2522/0007/G

Request for supplementary information adopted with a specific timetable.

Qdenga-
EMA/H/C/005155/WS2522/0008/G

Takeda GmbH, Lead Rapporteur: Sol Ruiz

Request for Supplementary Information adopted on 07.09.2023.

WS2525/G
Hexacima-
EMA/H/C/002702/WS2525/0151/G

Request for supplementary information adopted with a specific timetable.

Hexyon-
EMA/H/C/002796/WS2525/0155/G

MenQuadfi-

EMA/H/C/005084/WS2525/0025/G

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 07.09.2023.

WS2542/G
Ongentys-
EMA/H/C/002790/WS2542/0059/G

Request for supplementary information adopted with a specific timetable.

Ontilyv-
EMA/H/C/005782/WS2542/0014/G

Bial - Portela & C^a, S.A., Lead Rapporteur: Martina Weise

Request for Supplementary Information adopted on 14.09.2023.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

**Adtralza - tralokinumab -
EMA/H/C/005255/II/0008**

Positive Opinion adopted by consensus on 31.08.2023.

LEO Pharma A/S, Rapporteur: Jayne Crowe, "To update section 4.8 of the SmPC in order to update safety information based on interim results from the ECZTEND study, listed as a category 3 study in the RMP. This is a phase 3 open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with moderate-to-severe atopic dermatitis who participated in previous tralokinumab clinical trials.

In addition, the MAH is taking this opportunity to update the list of local representatives in the Package Leaflet."

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 01.06.2023, 09.02.2023.

**BIMERVAX - SARS-CoV-2 virus, variants
B.1.351-B.1.1.7, spike protein, receptor
binding domain fusion heterodimer -
EMA/H/C/006058/II/0002**

Request for supplementary information adopted with a specific timetable.

Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Submission of the final report from study HIPRA-HH-1 listed as a category 3 study in the RMP. This is a phase I/IIa study to evaluate safety and immunogenicity of Recombinant protein RBD fusion dimer candidate vaccine against SARS-COV-2 in adult healthy volunteers."

Request for Supplementary Information adopted on 31.08.2023.

**BIMERVAX - sars-cov-2 virus, variants
b.1.351-b.1.1.7, spike protein, receptor
binding domain fusion heterodimer -
EMA/H/C/006058/II/0004**

Request for supplementary information adopted with a specific timetable.

See 9.1

Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and immunogenicity information after a fourth dose based on interim results from study HIPRA-HH-2 listed as a category 3 study in the RMP; this is A Phase IIb, Double-Blind, Randomised, Active -

Controlled, Multicentre, Non-Inferiority Trial Followed By A Phase III, Single-Arm, Open-Label Trial To Assess Immunogenicity And Safety Of A Booster Vaccination With A Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-COV-2 In Adults Fully Vaccinated Against Covid-19 Followed By An Extension Period To Study A Fourth Dose Administration Of PHH-1V. The Package Leaflet is updated accordingly. In addition, the MAH submitted the full user consultation with target patient groups.” Request for Supplementary Information adopted on 14.09.2023.

BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0053/G, Orphan
Amgen Europe B.V., Rapporteur: Alexandre Moreau, “A grouped application consisting of: Type II (C.I.4): Update of sections 4.2, 5.1 and 6.6 of the SmPC in order to update the dexamethasone premedication guidance for paediatric patients with relapsed/refractory and high-risk first relapsed ALL, to add dexamethasone premedication information from study MT103-205 and study 20120215, and to add a statement that the administration of Blincyto for BSA of less than 0.4 m² has not been established. In addition, the MAH took the opportunity to update the name of ATC pharmacological subgroup according to WHO ATC Index and to delete “intravenous catheter” from the important note statement regarding flushing and to introduce minor editorial changes to the PI. The Package Leaflet is updated accordingly.
Type IB (C.I.11.z): Update of the due dates for post-authorisation safety studies 20150136 and 20180130 in the Annex II D in order to align with the RMP version 16.0, following commitment agreed on during procedure EMEA/H/C/003731/IB/0050.” Request for Supplementary Information adopted on 14.09.2023.

Request for supplementary information adopted with a specific timetable.

Brilique - ticagrelor - EMEA/H/C/001241/II/0061
AstraZeneca AB, Rapporteur: Patrick Vrijlandt, “Update of sections 4.2 and 4.4 of the SmPC in order to include a warning related to Single Antiplatelet Therapy (SAPT) in Patients with Acute Coronary Syndrome (ACS) who have

Request for supplementary information adopted with a specific timetable.

See 9.1

undergone a Percutaneous Coronary Intervention (PCI) procedure and who have an increased risk of bleeding based on literature.” Request for Supplementary Information adopted on 14.09.2023.

**Brintellix - vortioxetine -
EMA/H/C/002717/II/0038**

Positive Opinion adopted by consensus on 14.09.2023.

H. Lundbeck A/S, Rapporteur: Karin Janssen van Doorn, “Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to include clinically relevant information on the efficacy, safety, tolerability, and PK of vortioxetine in the paediatric population based on final results from studies 12709A, 12712A and 12712B.

Study 12709A is an interventional, randomized, double-blind, placebo-controlled, active-reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major Depressive Disorder (MDD) to evaluate efficacy and safety. Whereas studies 12712A and 12712B are 2 open-label, long-term safety and efficacy studies in children and adolescents: one 6-month extension study (study 12712A) to studies 12709A and 12710A, and one 18-month extension study (study 12712B) to study 12712A. In addition, updates are proposed in section 4.5 and package leaflet section 2 in relation to NSAIDs as well as updates to the package leaflet section 4 to align SmPC wording on sexual dysfunction.

The Package Leaflet is updated accordingly.” Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 22.06.2023, 30.03.2023, 15.12.2022.

**Cometriq - cabozantinib -
EMA/H/C/002640/II/0053, Orphan**

Positive Opinion adopted by consensus on 14.09.2023.

Ipsen Pharma, Rapporteur: Peter Mol, “Update of section 4.8 of the SmPC in order to add embolism arterial to the list of adverse drug reactions (ADRs) with frequency Uncommon based on literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 13.07.2023.

**COMIRNATY - covid-19 mrna vaccine
(nucleoside-modified) -**

Positive Opinion adopted by consensus on

EMA/H/C/005735/II/0186/G

14.09.2023.

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson, "Grouped application consisting of:

C.I.13: Submission of the final report from sub-study 6 for study WI235284 (Emory) listed as a category 3 study in the RMP. This was a test-negative design study to determine the Respiratory Syncytial Virus (RSV) burden and outcomes in pregnant women and older adults requiring hospitalisation. Sub-study 6 was aimed to estimate the effectiveness of 2 doses of COVID-19 mRNA vaccine against hospitalisation due to acute respiratory illness due to SARS-CoV-2 infection.

C.I.13: Submission of the final report from sub-study WI255886 (Bristol) listed as a category 3 study in the RMP. This was a test-negative design study to estimate the effectiveness of 2 doses of the BNT162b2 vaccine against hospitalisation for lower respiratory tract infection due to SARS-CoV-2 infection."

Opinion adopted on 14.09.2023.

Dovprela - pretomanid -**EMA/H/C/005167/II/0013, Orphan**

Positive Opinion adopted by consensus on 14.09.2023.

Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to change posology recommendations of linezolid, update frequency information of several adverse drug reactions as well as to update clinical efficacy information based on final results from ZeNix (NC007) study listed as a specific obligation (SOB/001) in the Annex II. ZeNix study is a phase III partially blinded, randomised trial assessing the safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary infection of either extensively drug resistant tuberculosis (XDR-TB), pre-XDR-TB or treatment intolerant or non-responsive multi-drug resistant tuberculosis (MDR-TB). The Package Leaflet (PL) is updated accordingly. As a result of this variation, the SmPC, Annex II and PL are also updated to reflect the completion of the specific obligation and the CHMP recommendation to grant a marketing authorisation no longer subject to specific obligations.

See 9.1

In addition, the MAH took the opportunity to

implement editorial changes in the SmPC and PL and to update the list of local representatives in the PL.

In addition, the CHMP, having considered the application as set out in the appended assessment report and having reviewed the data submitted by the marketing authorisation holder including the evidence concerning compliance with specific obligations, is of the opinion that the risk-benefit balance of the above mentioned medicinal product remains favourable, that all specific obligations laid down in Annex II have been fulfilled and that comprehensive data supports a favourable benefit-risk balance of the above mentioned medicinal product. Therefore, pursuant to Article 14-a(8) of Regulation (EC) No 726/2004, the CHMP recommends by consensus the granting of a marketing authorisation in accordance with Article 14(1) of Regulation (EC) No 726/2004 for the above mentioned medicinal product for which the draft Summary of Product Characteristics is set out in Annex I.”

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.

**Dupixent - dupilumab -
EMA/H/C/004390/II/0072**

Positive Opinion adopted by consensus on 31.08.2023.

Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update the safety and efficacy information relevant to patients with hand and foot Atopic Dermatitis based on the results from study R668-AD-1924. This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand and Foot Dermatitis.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 22.06.2023.

**Fintepla - fenfluramine -
EMA/H/C/003933/II/0018, Orphan**

Positive Opinion adopted by consensus on 31.08.2023.

UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, “Update of sections 4.8 and 5.1 of the SmPC in order to update the summary of the safety profile and list of adverse drug

reactions for Dravet Syndrome and to update clinical efficacy information, following the assessment of the Article 46 procedure LEG/009 based on final results from study 3 (study 1501/1502 Part 2). The Package Leaflet is updated accordingly. In addition, editorial updates and corrections were implemented in the Product Information.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 14.04.2023.

**GONAL-f - follitropin alfa -
EMA/H/C/000071/II/0158**

Positive Opinion adopted by consensus on 31.08.2023.

Merck Europe B.V., Rapporteur: Patrick Vrijlandt, “Update of sections 4.2 and 4.4 of the SmPC in order to align the wording with current clinical practice and to remove Estradiol and follicle number thresholds associated with signs of Ovarian Hyperstimulation Syndrome (OHSS), based on literature and clinical guidelines. An update of section 4.4. of the SmPC of the higher strengths (1050 IU/1.75 ml, 450 IU/0.75 mL) was included as well, in order to highlight the presence of benzyl alcohol and latex in these presentations.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 20.04.2023.

HEPLISAV B - Hepatitis B surface antigen (rDNA) - EMA/H/C/005063/II/0026

Positive Opinion adopted by consensus on 14.09.2023.

Dynavax GmbH, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to add a 4-dose regimen posology for patients with renal insufficiency including those undergoing haemodialysis and to update safety and pharmacodynamic information based on final results from study HBV-24 “An Open-label, Single Arm Study, Evaluating the Immunogenicity and Safety of HEPLISAV-B in Adults With End-Stage Renal Disease Undergoing Hemodialysis”. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make some editorial updates to the PI mainly to align the wording with the QRD guidance and templates.”

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 20.07.2023.

**Imbruvica - ibrutinib -
EMA/H/C/003791/II/0082**

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Submission of the final report from study PCI-32765CAN3001 in order to address the Post-Authorisation Measure (MEA017); this is a phase 3b, multicenter, open-label long-term extension study designed to collect long-term safety data."
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on 31.08.2023.

**INREBIC - fedratinib -
EMA/H/C/005026/II/0017, Orphan**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol, "Update of sections 4.4 and 4.5 of the SmPC in order to update drug-drug interaction information with dual inhibitors of CYP3A4 and CYP2C19, based on final results from study FEDR-CP-004; this is a phase 1, open-label study to evaluate the effect of a dual CYP2C19 and CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fedratinib in healthy adult subjects."
Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

**Instanyl - fentanyl -
EMA/H/C/000959/II/0077**

Takeda Pharma A/S, Rapporteur: Alexandre Moreau, "Update of section 4.8 of the SmPC in order to add hypersensitivity, anaphylactic reaction and anaphylactic shock to the list of adverse drug reactions (ADRs) with frequency not known based on a cumulative review on safety databases, clinical trials data, fentanyl labels and scientific literature. The Package Leaflet is updated accordingly."
Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted on 20.07.2023.

Positive Opinion adopted by consensus on 14.09.2023.

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0136**

Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, "Update of section 5.1 of the SmPC in order to provide the final OS data (including analyses/KM plots from favourable prognosis subgroups) following the assessment of procedure II/0104, based on results from study

Positive Opinion adopted by consensus on 31.08.2023.

E7080-G000-307/KEYNOTE 581 (REC); A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR). In addition, the due date for the final study report of Keynote 054 was updated in Annex II.”
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 13.07.2023, 25.05.2023.

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0139**

Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, “Update of section 5.1 of the SmPC in order to update clinical information, based on results from study KEYNOTE-716 listed as a PAES in the Annex II. This is a randomized, double-blind phase 3 study of adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. The Annex II is updated accordingly.”
Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0141**

Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, “Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-826; this is a phase 3 randomized, double-blind, placebo-controlled trial of pembrolizumab (MK-3475) plus chemotherapy versus chemotherapy plus placebo for the first-line treatment of persistent, recurrent, or metastatic cervical cancer. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Opinion adopted on 14.09.2023.

Positive Opinion adopted by consensus on 14.09.2023.

**Kisplyx - lenvatinib -
EMA/H/C/004224/II/0055**

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, “Update of section 5.1 of the SmPC in order to update efficacy information in first-line treatment of patients with renal cell carcinoma (in combination with pembrolizumab), based on the OS final analysis for the overall population from study E7080-G000-307/KEYNOTE 581; this is a multicenter, randomized, open-label, phase

Positive Opinion adopted by consensus on 31.08.2023.

3 study comparing the efficacy and safety of lenvatinib in combination with either pembrolizumab or everolimus versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma (RCC).”
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 13.07.2023, 25.05.2023.

Koselugo - selumetinib - EMEA/H/C/005244/II/0013, Orphan
AstraZeneca AB, Rapporteur: Alexandre Moreau,
“Update of sections 4.2 and 5.2 of the SmPC in order to update the recommended dosage regimen to remove the fasting state and update pharmacokinetic information, based on the final results from study D1346C00015; this is a phase 1, single-arm, sequential study to evaluate the effect of food on the gastrointestinal tolerability and pharmacokinetics of selumetinib after multiple doses in adolescent children with neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PN). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted on 22.06.2023.

Positive Opinion adopted by consensus on 14.09.2023.

Kyprolis - carfilzomib - EMEA/H/C/003790/II/0058, Orphan
Amgen Europe B.V., Rapporteur: Carolina Prieto Fernandez, “Submission of the final report from study 20160275 (CANDOR). This is a randomized, open-label, Phase 3 study comparing carfilzomib, dexamethasone, and daratumumab to carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.”
Request for Supplementary Information adopted on 14.09.2023.

Request for supplementary information adopted with a specific timetable.

Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0033
AstraZeneca AB, Rapporteur: Larisa Gorobets,
“Update of section 4.8 of the SmPC to include information on constipation to the summary of safety profile and to add constipation to the list of adverse drug reactions (ADRs) with frequency Common based on literature review and MAH

Request for supplementary information adopted with a specific timetable.

safety database. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes to the PI.”

Request for Supplementary Information adopted on 07.09.2023.

**Lonquex - lipegfilgrastim -
EMA/H/C/002556/II/0080**

Teva B.V., Rapporteur: Outi Mäki-Ikola, “Update of section 4.4 of the SmPC in order to add a class-effect warning risk of Acute Myeloid Leukaemia and Myelodysplastic Syndrome in breast and lung cancer patients in conjunction with chemotherapy and/or radiotherapy based on the cumulative review of literature and MAH safety database. The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

**LUMYKRAS - sotorasib -
EMA/H/C/005522/II/0011**

Amgen Europe B.V., Rapporteur: Alexandre Moreau, “Update of sections 4.2 and 4.5 of the SmPC in order to update information regarding the co-administration of sotorasib with acid reducing agents, based on the results from study 20220024; this is a phase 1, single-center, open-label drug-drug interaction study to evaluate the impact of omeprazole, a proton pump inhibitor, on the pharmacokinetics of sotorasib co-administered with an acidic beverage in healthy volunteers. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 20.07.2023.

Positive Opinion adopted by consensus on 14.09.2023.

**Lupkynis - voclosporin -
EMA/H/C/005256/II/0010**

Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Kristina Dunder, “Submission of the final study report from AUR-VCS-2016-02 (AURORA 2) Kidney Biopsy Substudy, listed as a category 3 study in the RMP.

The AURORA 2 extension trial included an optional biopsy substudy which was designed to assess renal histology from tissue samples taken prior to and after approximately 18

Request for supplementary information adopted with a specific timetable.

months of randomized treatment with voclosporin or placebo.”
Request for Supplementary Information adopted on 14.09.2023.

**Mayzent - siponimod -
EMA/H/C/004712/II/0023**

Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, “Update of section 5.1 of the SmPC in order to present data on the effect of siponimod on delaying the progression to EDSS ≥ 7 (time-to-wheelchair) based on post-hoc analysis of study CBAF312A2304 (EXPAND).”

Request for Supplementary Information adopted on 14.09.2023.

Request for supplementary information adopted with a specific timetable.

**Mounjaro - tirzepatide -
EMA/H/C/005620/II/0010**

Eli Lilly Nederland B.V., Rapporteur: Martina Weise, “Update of section 4.8 of the SmPC in order to add ‘anaphylactic reaction’ and ‘angioedema’ to the list of adverse drug reactions (ADRs) with frequency rare, based on reviews of post-marketing safety data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI.”

Request for Supplementary Information adopted on 07.09.2023.

Request for supplementary information adopted with a specific timetable.

**Mylotarg - gemtuzumab ozogamicin -
EMA/H/C/004204/II/0030, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, “Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy, pharmacokinetic and safety information based on interim results from study WI203680 - MyeChild 01-International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy. This is a dose finding sub-study aimed to identify the optimum tolerated number of doses of GO 3 mg/m² (up to a maximum of 3 doses) which can be combined safely with AraC plus mitoxantrone or liposomal DAUNO in induction therapy.”

Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

**Nexviadyme - avalglucosidase alfa -
EMA/H/C/005501/II/0008**

Sanofi B.V., Rapporteur: Christian Gartner,
"Update of sections 4.4, 4.8, 5.1 and 5.2 of the
SmPC in order to update the list of adverse drug
reactions (ADRs) and to update the safety and
efficacy information, based on interim results
from the open-label extension period of study
EFC14028 as well as pooled safety and
immunogenicity data. EFC14028 is a phase 3
randomized, multicenter, multinational, double-
blinded study comparing the efficacy and safety
of repeated biweekly infusions of
avalglucosidase alfa and alglucosidase alfa in
treatment naïve patients with late-onset Pompe
disease. The Package Leaflet is updated
accordingly. In addition, the MAH took the
opportunity to introduce minor editorial changes
to the PI."

Request for Supplementary Information adopted
on 14.09.2023, 08.06.2023.

Request for supplementary information adopted
with a specific timetable.

**Nexviadyme - avalglucosidase alfa -
EMA/H/C/005501/II/0012**

Sanofi B.V., Rapporteur: Christian Gartner,
"Submission of the final report from study
LTS13769 listed as a category 3 study in the
RMP. This is an interventional, open-label,
multicenter, multinational extension study to
evaluate long-term safety and pharmacokinetics
of repeated biweekly infusions of
avalglucosidase alfa in patients with Pompe
disease."

Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

**Norvir - ritonavir -
EMA/H/C/000127/II/0169**

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Patrick Vrijlandt, "Update of
sections 4.3 and 4.5 of the SmPC in order to
remove information regarding the DDI with
piroxicam based on a review of clinical studies,
post-marketing data and literature. The Package
Leaflet is updated accordingly."

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted
on 06.07.2023.

Positive Opinion adopted by consensus on
31.08.2023.

**NUVAXOVID - Covid-19 Vaccine
(recombinant, adjuvanted) -
EMA/H/C/005808/II/0054**

Positive Opinion adopted by consensus on
31.08.2023.

Novavax CZ, a.s., Rapporteur: Patrick Vrijlandt, "Submission of the final report from study 702-111; this is a non-clinical study to assess the immunogenicity and protective efficacy of sub-protective doses of SARSCoV-2 rS with Matrix-M adjuvant in rhesus macaques."

Opinion adopted on 31.08.2023.

**Opzelura - ruxolitinib -
EMA/H/C/005843/II/0003**

Incyte Biosciences Distribution B.V.,
Rapporteur: Peter Mol, "Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to update posology, safety and efficacy information based on final results from study INCB 18424-308; this is a Phase III, double-blind, vehicle-controlled, randomized withdrawal and treatment-extension study to assess the long-term efficacy and safety of ruxolitinib cream in participants with vitiligo (TRuE-V LTE). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."
Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

**Paxlovid - nirmatrelvir / ritonavir -
EMA/H/C/005973/II/0040/G**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Grouped application comprising two type II variations as follows:
- Update of section 4.3 of the SmPC in order to add more information for medicinal products such as finerenone, naloxegol, lumacaftor/ivacaftor, etc, under medicinal products that are that are highly dependent on CYP3A for clearance or potent CYP3A inducer which, therefore, could lead to serious and/or life-threatening reactions if co-administered with Paxlovid.
- Update of section 4.5 of the SmPC in order to add drug-drug interaction information regarding co-administration of Paxlovid with different medicinal products that are metabolised by CYP3A4 or CYP2D6, transported by P-gp, or induce CYP3A4."
Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted on 22.06.2023.

Positive Opinion adopted by consensus on 14.09.2023.

**Qutenza - capsaicin -
EMA/H/C/000909/II/0060**

Positive Opinion adopted by consensus on

<p>Grunenthal GmbH, Rapporteur: Bruno Sepodes, "Update of sections 4.2 and 5.1 of the SmPC in order to update guidance to healthcare professionals regarding progressive response with repeated treatments and to include additional information, based on recently published literature and clinical data." Opinion adopted on 14.09.2023.</p>	<p>14.09.2023.</p>
<p>RINVOQ - upadacitinib - EMEA/H/C/004760/II/0034 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Submission of the final report from study M13-542, listed as a category 3 study in the RMP. This is a phase 3, randomized, double-blind study comparing upadacitinib (ABT-494) to placebo on stable conventional synthetic disease-modifying anti rheumatic drugs (csDMARDs) in subjects with moderately to severely active rheumatoid arthritis with inadequate response or intolerance to biologic DMARDs (bDMARDs)." Opinion adopted on 14.09.2023. Request for Supplementary Information adopted on 08.06.2023.</p>	<p>Positive Opinion adopted by consensus on 14.09.2023.</p>
<p>RINVOQ - upadacitinib - EMEA/H/C/004760/II/0035 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Submission of the final report from study M13-549 listed as a category 3 study in the RMP. This is a Phase III, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs." Opinion adopted on 14.09.2023. Request for Supplementary Information adopted on 08.06.2023.</p>	<p>Positive Opinion adopted by consensus on 14.09.2023.</p>
<p>Rukobia - fostemsavir - EMEA/H/C/005011/II/0011 ViiV Healthcare B.V., Rapporteur: Janet Koenig, "Update of section 5.1 of the SmPC in order to update cross-resistance information based on results from virology study aimed at further characterisation of HIV-1 gp120 amino acid polymorphism E202."</p>	<p>Positive Opinion adopted by consensus on 14.09.2023.</p>

Opinion adopted on 14.09.2023.

**Rybelsus - semaglutide -
EMA/H/C/004953/II/0036**

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt,
"Update of sections 4.7 and 4.8 of the SmPC in
order to add 'Dizziness' to the list of adverse
drug reactions (ADRs) with frequency common
and update instructions for driving and using
machines. The Package Leaflet is updated
accordingly."

Opinion adopted on 14.09.2023.

Positive Opinion adopted by consensus on
14.09.2023.

**Saphnelo - anifrolumab -
EMA/H/C/004975/II/0007**

AstraZeneca AB, Rapporteur: Outi Mäki-Ikola,
"Update of sections 4.4, 4.8, 5.1 and 5.2 of the
SmPC based on final results from study
D3461C00009 listed as an additional
pharmacovigilance activity in the RMP; this is a
multicentre, randomised, double-blind, placebo-
controlled Phase III extension study to
characterise the long-term safety and
tolerability of anifrolumab in adult subjects with
active systemic lupus erythematosus. In
addition, the MAH took the opportunity to
implement minor changes to sections 4.2 and
6.6 of the SmPC and to the Package Leaflet. In
addition, the MAH took the opportunity to
update the list of local representatives in the
Netherlands in the Package Leaflet."

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted
on 20.07.2023, 14.04.2023.

Positive Opinion adopted by consensus on
14.09.2023.

**Scemblix - asciminib -
EMA/H/C/005605/II/0004/G, Orphan**

Novartis Europharm Limited, Rapporteur: Janet
Koenig, "Grouped application comprising two
type II variations as follows:

- Submission of the final reports from studies
DMPK-R2200470 (REC). This is an in vitro
evaluation of inducibility of OATP1V1, MDR1 and
CYP3A4 by asciminib using human hepatocytes.
- Submission of the final report from study
DMPK-R2270399 (REC). This is a physiologically
based PK modelling and simulations to
characterise the effect of cyclodextrins on the
exposure of asciminib."

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted

Positive Opinion adopted by consensus on
31.08.2023.

on 15.06.2023.

**Spinraza - nusinersen -
EMA/H/C/004312/II/0029, Orphan**
Biogen Netherlands B.V., Rapporteur: Bruno Sepodes, "Update of section 5.3 of the SmPC in order to update non-clinical information based on final results from study P058-17-02. This is a 24-month carcinogenicity study when administered by subcutaneous injection in mouse."
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 22.06.2023.

Positive Opinion adopted by consensus on 31.08.2023.

**Synagis - palivizumab -
EMA/H/C/000257/II/0132**
AstraZeneca AB, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update safety information based on results from safety data evaluations from multiple sources, including the clinical Study W00-350, post-Marketing Clinical Surveillance Programme (REACH), literature searches and the AstraZeneca Global Patient Safety database.
The MAH took the opportunity to change the details of the Local Representatives in the PL."
Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted on 22.06.2023, 30.03.2023.

Positive Opinion adopted by consensus on 14.09.2023.

**Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) -
EMA/H/C/003982/II/0126**
MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of sections 4.2 and 5.1 of the SmPC in order to add information on interchangeable use of Vaxelis with other hexavalent vaccines based on final results from study V419-016.
In addition, the MAH took this opportunity to introduce minor editorial changes."
Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) -

Request for supplementary information adopted with a specific timetable.

EMA/H/C/003982/II/0128

MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of sections 4.5 and 5.1 of the SmPC in order to add drug-drug interaction information with meningococcal B conjugate vaccine and update immunogenicity information for anti-PRP (Hib) following co-administration with meningococcal B vaccine based on final results from study OVG 2018/05 - Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy; this is an open-label, non-inferiority, randomized clinical trial that compared the immune response and assessed the safety of Vaxelis and control vaccine (Infanrix hexa) when co-administered with 4 component meningococcal B vaccine (4CMenB) along with other routine infant vaccines. The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 07.09.2023.

Veltassa - patiomer -**EMA/H/C/004180/II/0034/G**

Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Grouped application consisting of three Type II variations (C.I.4):

Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy information based on final results from study PAT-CR-302 (Diamond); this is a Phase 3b international, double-blind, placebo-controlled, randomised withdrawal, parallel-group study of patiomer for the management of hyperkalaemia (HK) in patients receiving renin-angiotensin-aldosterone system inhibitors (RAASi) for the treatment of heart failure (HF). In addition, the MAH took the opportunity to implement editorial changes to the SmPC.

Update of sections 4.8 and 5.1 of the SmPC in order to update safety information based on a pooled safety database. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.

Update of section 4.8 of the SmPC in order to add "Hypersensitivity" to the list of adverse drug reactions (ADRs) with frequency "not known", based on post-marketing data."

Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 14.09.2023.

Vyndaqel - tafamidis - EMEA/H/C/002294/II/0087, Orphan
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC in order to remove the adverse reaction 'vaginal infection' based on a search of cumulative post-marketing cases. The Package Leaflet is updated accordingly. In addition, the MAH takes the opportunity to update the company logo on the Package Leaflet."
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 20.07.2023.

Positive Opinion adopted by consensus on 31.08.2023.

Xevudy - sotrovimab - EMEA/H/C/005676/II/0018
Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of section 5.1 of the SmPC with data on the in vitro activity of sotrovimab in a pseudotyped virus assay against the Omicron XBB.1.5 and BN.1 spike variants (PC-23-0104), the Omicron CH.1.1 spike variant (PC-23-0108) and the Omicron BR.2 and XBF spike variants (PC-23-0117), as well as data on the in vitro activity of sotrovimab in a live virus assay against the SARS-CoV-2 XBB.1.5 variant (PC-23-0106) and the CH.1.1 variant (PC-23-0118)."
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on 31.08.2023.

Xevudy - sotrovimab - EMEA/H/C/005676/II/0019/G
Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to update posology recommendations and administration instructions and to update efficacy, pharmacokinetic and safety information, based on results from studies COMET-TAIL (phase 3 study and safety substudy; 217114), COMET-PEAK (216912), Japan-PK (217653) and BLAZE-4, and from a Population PK (PopPK) report. These clinical studies were conducted to assess the efficacy, safety and tolerability of sotrovimab given intramuscularly (IM) versus intravenously (IV) for the treatment of mild/moderate coronavirus disease 2019

Request for supplementary information adopted with a specific timetable.

(COVID-19) in high-risk, non-hospitalized patients (COMET-TAIL phase 3 study); to assess the safety and tolerability of single ascending dose of sotrovimab (COMET-TAIL safety substudy); to assess safety, tolerability, PK and viral pharmacodynamics (PD) of sotrovimab in participants with early mild-to-moderate COVID-19 (COMET-PEAK); to assess PK, safety and tolerability of IV and IM sotrovimab in healthy Japanese and Caucasian participants (Japan-PK); and to evaluate the impact of monoclonal antibodies such as LY3819253 + sotrovimab on viral clearance and clinical outcomes in participants with COVID-19 illness (BLAZE-4). The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 14.09.2023.

Zejula - niraparib -

EMA/H/C/004249/II/0044, Orphan

GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, “Submission of the modelling report with the results from the population pharmacokinetic and exposure-response modelling exercises (REC 7).”

Request for Supplementary Information adopted on 07.09.2023.

Request for supplementary information adopted with a specific timetable.

Zokinvy - lonafarnib -

EMA/H/C/005271/II/0004, Orphan

EigerBio Europe Limited, Rapporteur: Patrick Vrijlandt, “Update of sections 4.2, 4.4, 4.5 and 6.6 of the SmPC in order to include updated drug-drug interaction information based on the final results from Drug-Drug Interaction study EIG-LNF-021. This is a Phase I, open-label, single-centre, two period, single sequence study evaluating the effect of autoinhibition, and the effects of fluconazole, a non-specific strong CYP2C9 inhibitor and moderate inhibitor of CYP2C9 and CYP3A, on the multiple-dose pharmacokinetics of lonafarnib. The Package Leaflet is updated accordingly.”

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 22.06.2023.

Positive Opinion adopted by consensus on 14.09.2023.

WS2415

Vfend-EMA/H/C/000387/WS2415/0148

Pfizer Europe MA EEIG, Lead Rapporteur: Patrick Vrijlandt, “Update of section 4.4 of the

Positive Opinion adopted by consensus on 31.08.2023.

SmPC to include increased risk of skin toxicity with concomitant use of voriconazole and methotrexate and potentially other drugs associated with ultraviolet (UV) reactivation to the current warning on photosensitivity skin reactions, based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the WSA took the opportunity to implement editorial changes to sections 4.4 and 4.5 of the SmPC.”
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 26.04.2023.

WS2460
Elebrato Ellipta-
EMA/H/C/004781/WS2460/0032
Trelegy Ellipta-
EMA/H/C/004363/WS2460/0029

GlaxoSmithKline Trading Services Limited, Lead Rapporteur: Finbarr Leacy, “Update of sections 4.4 and 4.8 of the SmPC in order to add ‘Anxiety’, ‘Tremor’, ‘Muscle spasms’, ‘Hyperglycaemia’ and ‘Palpitations’ to the list of adverse drug reactions (ADRs) with frequency rare, based on an internal safety review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 25.05.2023.

Positive Opinion adopted by consensus on 31.08.2023.

WS2485
Incruse Ellipta-
EMA/H/C/002809/WS2485/0037
Rolufta Ellipta-
EMA/H/C/004654/WS2485/0021

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, “Update of sections 4.2, 4.6 and 4.8 of the SmPC in order to add ‘Dysphonia’ and ‘Oropharyngeal pain’ to the list of adverse drug reactions (ADRs) with frequency rare, and to update the wording regarding the administration instructions and for pregnancy and breast-feeding. The Package Leaflet and Labelling are also updated. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.

on 14.09.2023, 20.07.2023.

WS2488

Aluvia-EMA/H/W/000764/WS2488/0118

Kaletra-EMA/H/C/000368/WS2488/0197

Norvir-EMA/H/C/000127/WS2488/0168

AbbVie Deutschland GmbH & Co. KG, Lead
Rapporteur: Patrick Vrijlandt, "To update section 4.5 in order to align with the text in the Prezista product information, and reflect and additional Drug-Drug Interaction with dabigatran etexilate and edoxaban following the final assessment report for Norvir LEG 033.12. The Package Leaflet is updated accordingly. Furthermore, the MAH has taken the opportunity to implement minor editorial changes to the Romanian and Norwegian Patient Information Leaflets."
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on 31.08.2023.

WS2489/G

Kinzalmono-

EMA/H/C/000211/WS2489/0119/G

Micardis-

EMA/H/C/000209/WS2489/0127/G

Pritor-

EMA/H/C/000210/WS2489/0132/G

Boehringer Ingelheim International GmbH, Lead
Rapporteur: Paolo Gasparini, "Grouped application consisting of:

C.I.4: Update of section 4.8 of the SmPC in order to include "hyponatremia" to the list of adverse drug reactions (ADRs) with frequency "rare", based on post-marketing data and literature;

C.I.z (Type IB unforeseen): Update of section 4.7 of the SmPC to replace the terms "dizziness" and "drowsiness" by "syncope" and "vertigo" to align with adverse reactions table in section 4.8 of SmPC.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet; bring the PI in line with the latest QRD template version 10.3; and to implement editorial changes to the SmPC.

The MAH withdrew the variation to update of section 4.2 to include the possibility of using the combination of telmisartan and amlodipine for lowering blood pressure. The MAH informed that the reason for the withdrawal was that an agreement on the wording could not be reached

Positive Opinion adopted by consensus on 14.09.2023.

within the procedure.”

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 20.07.2023, 15.06.2023.

WS2509/G

Anoro Ellipta-

EMA/H/C/002751/WS2509/0042/G

Laventair Ellipta-

EMA/H/C/003754/WS2509/0045/G

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Finbarr Leacy, “Grouped application comprising two type II variations (C.I.4) as follows:

- Update of section 4.8 of the SmPC in order to delete 'rash' from the list of adverse drug reactions (ADRs) with frequency uncommon based on the cumulative review of the MAH safety database, clinical trial data and literature.
- To include significant changes to sections 2, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.5 of the SmPC, sections 4, 5, 7 and 11 of the Labelling and sections 2, 3 and 6 of the Package Leaflet for the medicinal products Anoro and Laventair containing the active substances Umeclidinium Bromide and Vilanterol following the assessment of the medicinal products Trelegy and Rolufta Ellipta, which also contain the active substances fluticasone furoate, umeclidinium bromide and vilanterol, via procedure EMA/H/C/004363/R/0023 and EMA/H/C/004654/R/0019. The same wording is used for the combination product.

The Package Leaflet and Labelling are updated accordingly. The Annex II is updated. In addition, the MAH took the opportunity to introduce minor editorial changes and to bring the PI in line with the latest QRD template.”

Request for Supplementary Information adopted on 14.09.2023.

Request for supplementary information adopted with a specific timetable.

WS2520/G

Lyrica-

EMA/H/C/000546/WS2520/0124/G

Pregabalin Pfizer-

EMA/H/C/003880/WS2520/0052/G

Upjohn EESV, Lead Rapporteur: Peter Mol, “Grouped application comprising two type II as follows:

C.I.4 - Update of sections 4.4 and 5.1 of the SmPC in order to add information on potential

Request for supplementary information adopted with a specific timetable.

abuse in recreational drug users based on final results from study A0081365 "A Phase 4 Randomized Double-Blind Double-Dummy Placebo- and Active-Controlled Single-Dose Six-way Crossover Study Evaluating the Abuse Potential of Lyrica Taken Orally with Oxycodone HCl in Healthy Non-Drug Dependent Recreational Opioid Users".

A.6 - To change the ATC Code from N03AX16 to N02BF02."

Request for Supplementary Information adopted on 31.08.2023.

WS2523

Atectura Breezhaler-

EMA/H/C/005067/WS2523/0021

Bemrist Breezhaler-

EMA/H/C/005516/WS2523/0017

Energair Breezhaler-

EMA/H/C/005061/WS2523/0018

Zimbus Breezhaler-

EMA/H/C/005518/WS2523/0015

Novartis Europharm Limited, Lead Rapporteur: Finbarr Leacy, "Update of sections 5.3 and 6.6 of the SmPC in order to include a statement regarding the risk to the environment based on results from ERA study Mometasone furoate – Fish Sexual Development Test with Zebrafish (*Danio rerio*). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Opinion adopted on 07.09.2023.

Positive Opinion adopted by consensus on 07.09.2023.

WS2534

Abseamed-

EMA/H/C/000727/WS2534/0104

Binocrit-

EMA/H/C/000725/WS2534/0103

Epoetin alfa Hexal-

EMA/H/C/000726/WS2534/0103

Sandoz GmbH, Lead Rapporteur: Alexandre Moreau, "Update of section 4.4 of the SmPC in order to allow for iron supplementation in accordance with patient needs and up-to-date treatment guidelines by removing the restrictions to exclusively use the oral route of administration for iron supplementation. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI, bring it in line with the latest QRD template

Request for supplementary information adopted with a specific timetable.

version 10.3, align it with the reference product and update instructions for use.”

Request for Supplementary Information adopted on 31.08.2023.

B.5.3. CHMP-PRAC assessed procedures

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0016

Positive Opinion adopted by consensus on 14.09.2023.

Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Jean-Michel Dogné, “Submission of an updated RMP version 4 in order to update post-approval commitments. In addition, the MAH took the opportunity to update Annex II of the SmPC to expand the B4741015 PAES study protocol to sites in Europe and Israel for Apexxnar. B4741015 is a Phase 4 study using a test negative design to evaluate the effectiveness of Apexxnar against vaccine type radiologically confirmed community acquired pneumonia in adults ≥ 65 years of age.”

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 20.07.2023.

BESPONSA - inotuzumab ozogamicin - EMEA/H/C/004119/II/0026, Orphan

Request for supplementary information adopted with a specific timetable.

Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer, “Update of sections 4.2, 4.6, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information based on final results from studies ITCC-059 (WI203581) and INO-Ped-ALL-1 (WI235086). Study WI203581 is a Phase 1/2, multicenter, European, multi-cohort, open-label study in paediatric patients (≥ 1 and < 18 years of age) with R/R CD22-positive Acute Lymphoblastic Leukemia (ALL); and study WI235086 is an open-label, multi-center Phase 1 study to assess safety and tolerability of InO in Japanese paediatric patients with R/R CD22-positive ALL. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted.”

Request for Supplementary Information adopted on 14.09.2023.

GIVLAARI - givosiran - EMEA/H/C/004775/II/0013/G, Orphan

Positive Opinion adopted by consensus on 14.09.2023.

Alnylam Netherlands B.V., Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Martin Huber, "Submission of the final reports from studies ALN-AS1-003 (study 003) and ALN-AS1-002 (study 002) listed as a category 3 studies in the RMP. Study 003 is a phase 3 randomized, double-blind, placebo-controlled multicenter study with an open-label extension to evaluate the efficacy and safety of givosiran in patients with acute hepatic porphyrias, while study 002 is a multicenter, open-label extension study to evaluate the long-term safety and clinical activity of subcutaneously administered ALN AS1 in patients with acute intermittent porphyria who have completed a previous clinical study with ALN-AS1. The RMP version 2.2 has also been submitted."

Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 25.05.2023, 23.02.2023, 13.10.2022.

**Glivec - imatinib -
EMA/H/C/000406/II/0133**

Novartis Europharm Limited, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Monica Martinez Redondo, "Submission of the final report from study CSTI571I2201 - A European observational registry collecting efficacy and safety data in newly diagnosed paediatric Ph+ ALL patients treated with chemotherapy + imatinib ± HSCT, listed as an obligation in the Annex II of the Product Information. This study has been designed as an observational, multi-center registry to collect efficacy and safety data in Ph+ ALL paediatric patients (ages 1 to <18 years old) treated with chemotherapy + imatinib, with or without (± HSCT) primarily in European countries. The Annex II and the RMP (version 13.0) are updated accordingly."

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 12.05.2023.

Positive Opinion adopted by consensus on 31.08.2023.

**Increlex - mecasermin -
EMA/H/C/000704/II/0080**

Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, "Update of sections 4.2, 4.6 and 4.8 of the SmPC in order to modify administration instructions recommendation regarding the monitoring of

Request for supplementary information adopted with a specific timetable.

pre-prandial blood glucose in pre- prandial condition and in case of symptoms and to prevent the risk of lipohypertrophy, delete wording in the pregnancy section and update on number of patients with severe primary IGFD based on the cumulative review of safety database, scientific literature and clinical trials data. The Package Leaflet is updated accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Request for Supplementary Information adopted on 31.08.2023.

Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0035, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Peter Mol, PRAC Rapporteur: Martin Huber, “Update of sections 4.8 and 5.1 of the SmPC based on interim results from study VX19-445-107 (study 107) listed as a category 3 study in the RMP; this is a Phase III, open-label study evaluating the long-term safety and efficacy of VX445/TEZ/IVA combination therapy in subjects with cystic fibrosis who are 6 years of age and older. The RMP version 7.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 12.05.2023.

Positive Opinion adopted by consensus on 31.08.2023.

Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0039, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Peter Mol, PRAC Rapporteur: Martin Huber, “Update of sections 4.8 and 5.1 of the SmPC in order to update information based on final results from study VX17-445-105 (study 105); this is a phase 3, open-label, extension study evaluating the long-term safety and efficacy of ELX/TEZ/IVA treatment in cystic fibrosis (CF) subjects 12 years of age and older, homozygous, or heterozygous for the F508del-CFTR mutation who participated in study VX17-445-102 (study 102) or study VX17-445-103 (study 103). The RMP version 7.2 has also been

Request for supplementary information adopted with a specific timetable.

submitted.”

Request for Supplementary Information adopted on 31.08.2023.

**Lenvima - lenvatinib -
EMA/H/C/003727/II/0050**

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information based on final results from studies E7080-G000-207 and E7080-G000-230. Study E7080-G000-207 is a multicenter, open-label, Phase 1/2 study of lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma; study E7080-G000-230 is a multicenter, open-label, randomized Phase 2 study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with Relapsed or Refractory Osteosarcoma (OLIE). The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted.”

Request for Supplementary Information adopted on 14.09.2023.

Request for supplementary information adopted with a specific timetable.

**Lynparza - olaparib -
EMA/H/C/003726/II/0061**

AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, “Update of sections 4.8 and 5.1 of the SmPC in order to update the overall survival and safety information following procedure H/C/003726/II/0048, based on the final results from study D081SC00001 (PROpel), listed as a PAES in the Annex II; this is a randomised, double-blind, placebo-controlled, multicentre phase III study of olaparib plus abiraterone relative to placebo plus abiraterone as first-line therapy in men with metastatic castration resistant prostate cancer. The RMP version 27 has also been submitted.”

Request for Supplementary Information adopted on 31.08.2023, 06.07.2023.

Request for supplementary information adopted with a specific timetable.

**Lynparza - olaparib -
EMA/H/C/003726/II/0064**

AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, “Update of sections 4.8 and 5.1 of the SmPC to update the

Positive Opinion adopted by consensus on 31.08.2023.

results of a descriptive analysis of Overall Survival at seven years last subject randomised in study D0818C0001 (SOLO1). This is a Phase III randomised, double blind, placebo controlled, multicentre study in which advanced ovarian cancer patients with BRCA mutations who had responded following first-line platinum-based chemotherapy were randomised 2:1 to receive either Olaparib (300 mg bd, tablet formulation) or placebo. The RMP version 28 has also been submitted. In addition, the MAH took the opportunity to update section D of Annex II.”
Opinion adopted on 31.08.2023.

**Mavenclad - cladribine -
EMA/H/C/004230/II/0027**

Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of sections 4.5 and 4.6 of the SmPC in order to add information regarding the use of mavenclad with oral contraceptives based on the final study results from the drug-drug interaction study (MS 700568-0031). This is a randomized, double-blind, 2-period, 2-sequence, crossover Phase I study with a 1-month run-in period to examine the effect of cladribine tablets on the pharmacokinetics of a monophasic oral contraceptive containing ethinyl estradiol and levonorgestrel (microgynon) in pre-menopausal women with Relapsing Multiple Sclerosis (RMS). The Annex II and Package Leaflet are updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity implement editorial changes to sections 4.2 and 4.4 of the SmPC.”

Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

**NINLARO - ixazomib -
EMA/H/C/003844/II/0045, Orphan**

Takeda Pharma A/S, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Ulla Wändel Liminga, “Submission of the Clinical Study Report (Addendum 2) for study C16019 listed as a Specific Obligation in the Annex II of the Product Information. This is a phase 3, randomized, double-blind, placebo-controlled study of single-agent oral ixazomib as maintenance therapy following autologous stem cell transplant (ASCT) for patients with newly

Positive Opinion adopted by consensus on 14.09.2023.

See 9.1

diagnosed multiple myeloma. In addition, the MAH proposes to remove NINLARO from the list of medicines subject to additional monitoring and to remove the black triangle from the SmPC. The Annex II and Package Leaflet are updated accordingly. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet.”
Request for Supplementary Information adopted on 14.09.2023.

Piqray - alpelisib -

EMA/H/C/004804/II/0018

Novartis Europharm Limited, Rapporteur:
Carolina Prieto Fernandez, PRAC Rapporteur:
Menno van der Elst, “Update of sections 4.5 and 5.2 of the SmPC in order to update drug-drug interaction information, based on final results from study BYL719A2111; this is a phase 1, open-label, fixed-sequence, two-period drug-drug interaction (DDI) study evaluating the PK probe substrates for CYP3A4, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 when administered either alone or in combination with repeated doses of alpelisib. The Annex II and Package Leaflet are updated accordingly. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives and to introduce minor editorial changes to the PI.”
Opinion adopted on 14.09.2023.

Request for Supplementary Information adopted on 22.06.2023, 16.03.2023.

Positive Opinion adopted by consensus on 14.09.2023.

TAGRISSO - osimertinib -

EMA/H/C/004124/II/0052

AstraZeneca AB, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst, “Update of section 5.1 of the SmPC in order to update efficacy information (final OS data) based on final results from study D5164C00001 (ADAURA) listed as a PAES in the Annex II; this is a Phase III, double-blind, randomised, placebo-controlled study, designed to assess the efficacy and safety of osimertinib versus placebo in patients with stage IB-IIIA epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC) who have undergone complete tumour resection, with or without postoperative

Request for supplementary information adopted with a specific timetable.

adjuvant chemotherapy. The RMP version 15 has also been submitted. In addition, the MAH took the opportunity to update Annex II section D of the PI and to implement editorial changes to the SmPC.”

Request for Supplementary Information adopted on 31.08.2023.

**Tecentriq - atezolizumab -
EMA/H/C/004143/II/0078**

Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of section 5.1 of the SmPC in order to include the final overall survival (OS) analysis results based on final results from study WO30070 listed as a PAES in the Annex II to fulfil ANX/PAE 003; this is a Phase III, multicenter, randomized, placebo-controlled study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma. The RMP version 27 has also been submitted. In addition, the MAH took the opportunity to update Annex II of the SmPC.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 06.07.2023.

Positive Opinion adopted by consensus on 31.08.2023.

**TEPMETKO - tepotinib -
EMA/H/C/005524/II/0009**

Merck Europe B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information based on results from study VISION (MS200095-0022); this is a Phase II, multicenter, open-label, single-arm study to evaluate the efficacy and safety/tolerability of the recommended dose of tepotinib in participants with advanced NSCLC of all histology types who tested positive for METex14 skipping alterations by next-generation sequencing in tissue (RNA-based) or plasma (circulating tumor DNA based). The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.”

Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on 31.08.2023.

**Translarna - ataluren -
EMA/H/C/002720/II/0069, Orphan**
PTC Therapeutics International Limited,

The CHMP adopted a negative opinion by consensus, recommending the refusal of the variation(s) to the terms of the marketing

Rapporteur: Peter Mol, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information following results from study PTC124-GD-041-DMD, listed as a specific obligation in the Annex II; This is a Phase 3 multicentre, randomised, double-blind, 18-month, placebo-controlled study, followed by a 18-month open label extension to confirm the efficacy and safety of ataluren in the treatment of ambulant patients with mnDMD aged 5 years or older.

Annex II and Annex IIB are updated to delete the SOB and to reflect the switch from conditional to full marketing authorisation. The Package Leaflet is updated accordingly. The RMP version 11.0 has also been submitted. Minor corrections were done to align the PI with the latest QRD templates."
Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted on 25.05.2023, 26.01.2023.

authorisation.

See 2.3 and 9.1

**Veklury - remdesivir -
EMA/H/C/005622/II/0050**

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, "Update of sections 4.2, 4.4, 4.8 and 5.2 of the SmPC in order to address the safety of remdesivir and its metabolites in patients with hepatic impairment and to update information on hepatic and coagulation laboratory abnormalities based on final results from study GS US 540 9014: "A phase 1 open-label, adaptive, single-dose study to evaluate the pharmacokinetics of remdesivir and its metabolite(s) in subjects with normal hepatic function and hepatic impairment", listed as a category 3 study in the RMP, and on safety data from post-marketing and clinical trials experience.

The Package Leaflet is updated accordingly. The RMP version 8.0 has also been updated. In addition, the MAH took the opportunity to submit Minor Linguistic Amendments (MLA) for Veklury."

Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted on 22.06.2023.

Positive Opinion adopted by consensus on 14.09.2023.

**WS2513
Copalia HCT-
EMA/H/C/001159/WS2513/0106**

Positive Opinion adopted by consensus on 14.09.2023.

Dafiro HCT-
EMA/H/C/001160/WS2513/0108
Exforge HCT-
EMA/H/C/001068/WS2513/0105

Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher, Lead PRAC
Rapporteur: Marie Louise Schougaard
Christiansen, "C.I.11.z - to confirm the
fulfilment of condition B to the Marketing
Authorisation of Exforge HCT Film-coated
Tablets (including its duplicates Dafiro HCT and
Copalia HCT) as set out by the Commission
Decision in the outcome of the assessment for
the impact of Article 5(3) scientific opinion on
nitrosamines in human medicinal products on
the opinion adopted pursuant to Article 31 of
Directive 2001/83/EC for angiotensin-II-
receptor antagonists (sartans) containing a
tetrazole group (attached as annex 1). Annex II
of the PI has been amended accordingly."
Opinion adopted on 14.09.2023.

B.5.4. PRAC assessed procedures

PRAC Led
EVUSHELD - tixagevimab / cilgavimab -
EMA/H/C/005788/II/0013
AstraZeneca AB, PRAC Rapporteur: Kimmo
Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola,
"Submission of an updated RMP version 5
succession 1 to remove the commitment to
conduct the post-authorisation safety study
(PASS) D8850R00006: A post-authorization
Observational Study of Women exposed to
EVUSHELD During Pregnancy (O-STEREO)."
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

PRAC Led
Fintepla - fenfluramine -
EMA/H/C/003933/II/0017, Orphan
UCB Pharma SA, Rapporteur: Thalia Marie
Estrup Blicher, PRAC Rapporteur: Martin Huber,
PRAC-CHMP liaison: Janet Koenig, "Submission
of the updated RMP version 2.16 in order to
implement a targeted follow-up questionnaire
(FUQ) to further improve the collection of
follow-up information on cases of vascular heart
disease (VHD) and pulmonary arterial
hypertension (PAH) suggested by PRAC
following the assessment of procedure

Positive Opinion adopted by consensus on
31.08.2023.

EMA/H/C/PSUSA/00010907/202112.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 08.06.2023, 14.04.2023, 12.01.2023.

PRAC Led

Kengrexal - cangrelor -

EMA/H/C/003773/II/0031

Chiesi Farmaceutici S.p.A., PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Paolo Gasparini, “Submission of the final report from study ARCANGELO (Italian prospective study on CANGrELor), listed as a category 3 study in the RMP. This is a multicentre observational, prospective cohort study including patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. transitioning to either clopidogrel, prasugrel or ticagrelor per os. The primary objective is to assess the safety of cangrelor in a real-world setting, when administered in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). The safety of cangrelor is based on the incidence of any haemorrhage at 30 days post-PCI.

The RMP version 5.1 has also been submitted.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 14.04.2023.

Positive Opinion adopted by consensus on 31.08.2023.

PRAC Led

Mysimba - naltrexone hydrochloride / bupropion hydrochloride -

EMA/H/C/003687/II/0063

Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “To update sections 4.3, 4.4 and 4.5 of the SmPC to update and streamline the relevant wording on opioids following the assessment of PSUSA/00010366/202209 procedure. The Package Leaflet is updated accordingly. The RMP version 12.9 has also been submitted.”

Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

PRAC Led

Olumiant - baricitinib -

EMA/H/C/004085/II/0043

Eli Lilly Nederland B.V., PRAC Rapporteur: Adam

Request for supplementary information adopted with a specific timetable.

Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of an updated RMP version 22.1 in order to remove existing additional pharmacovigilance activities (category 3 studies): study I4V-MC-JAJA (JAJA) and study I4V-MC-JAJD (JAJD)."
Request for Supplementary Information adopted on 31.08.2023.

PRAC Led Positive Opinion adopted by consensus on 31.08.2023.

Plegridy - peginterferon beta-1A - EMEA/H/C/002827/II/0070

Biogen Netherlands B.V., PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study 105MS401. The objective of this study was to determine the incidence of serious adverse events (SAEs) in patients with relapsing forms of MS in routine clinical practice and to assess the overall long-term clinical effectiveness of peginterferon beta-1a in patients with relapsing forms of MS in routine clinical practice."
Opinion adopted on 31.08.2023.

PRAC Led Positive Opinion adopted by consensus on 31.08.2023.

Pravafenix - fenofibrate / pravastatin sodium - EMEA/H/C/001243/II/0034

Laboratoires SMB s.a., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Jean-Michel Race, "Submission of the final report from study POSE: Pravafenix Observational Study in Europe (EUPAS 13661), listed as a category 3 study in the RMP (MEA/007.10). This is an observational, three-year cohort comparative study on the safety of the fixed dose combination pravastatin 40 mg/ fenofibrate 160 mg (Pravafenix) versus statin alone in real clinical practice."
Opinion adopted on 31.08.2023.

PRAC Led Positive Opinion adopted by consensus on 31.08.2023.

Skilarence - dimethyl fumarate - EMEA/H/C/002157/II/0032

Almirall S.A, Rapporteur: Janet Koenig, PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study M-41008-44 listed as a category 3 study in the RMP. This is a non-interventional Post-Authorisation Safety Study titled 'A retrospective chart review to assess the effectiveness of the Skilarence risk minimisation activities in daily practice'. The RMP version 2.1

has also been submitted.”
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted
on 12.05.2023.

PRAC Led
**Stelara - ustekinumab -
EMA/H/C/000958/II/0100**
Janssen-Cilag International N.V., PRAC
Rapporteur: Rhea Fitzgerald, PRAC-CHMP
liaison: Jayne Crowe, “Update of section 4.6 of
the SmPC in order to update information on
pregnancy based on the final synoptic report
from study CNTO1275PSO4037 (OTIS); this is a
pregnancy exposure registry for Stelara. The
Package Leaflet is updated accordingly. The RMP
version 26.2 has also been submitted.”
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

PRAC Led
**TECFIDERA - dimethyl fumarate -
EMA/H/C/002601/II/0082**
Biogen Netherlands B.V., PRAC Rapporteur:
Martin Huber, PRAC-CHMP liaison: Martina
Weise, “Update of section 4.6 of the SmPC in
order to update information on pregnancy based
on results from study 109MS402 - Tecfidera
(dimethyl fumarate) Pregnancy Exposure
Registry, listed as a category 3 study in the
RMP; This is an observational study and aims to
address the safety concern of effects on
pregnancy outcome and prospectively evaluates
pregnancy outcomes in women with MS who
were exposed to a Registry-specified Biogen MS
product during the eligibility window for that
product.
The Package Leaflet is updated accordingly.
The RMP version 15.1 has also been submitted.
In addition, the MAH has taken the opportunity
to introduce editorial changes to the Product
Information.”
Request for Supplementary Information adopted
on 31.08.2023, 12.05.2023.

Request for supplementary information adopted
with a specific timetable.

PRAC Led
**Tecovirimat SIGA - tecovirimat -
EMA/H/C/005248/II/0006**
SIGA Technologies Netherlands B.V., PRAC
Rapporteur: Martin Huber, PRAC-CHMP liaison:
Martina Weise, “Submission of substantial
updates to the protocol of study SIGA-246-021

Request for supplementary information adopted
with a specific timetable.

See 9.1

listed as a specific obligation in the Annex II of the Product Information in order to reflect the transfer of sponsorship from SIGA Technologies, Inc. to the NIH Division of Microbiology and Infection Disease protocol. This is a phase 4, observational field study to evaluate safety and clinical benefit in tecovirimat-treated patients following exposure to variola virus and clinical diagnosis of smallpox disease. The Annex II and the RMP submitted version 1.2 are updated accordingly.”

Request for Supplementary Information adopted on 14.09.2023, 25.05.2023, 14.04.2023.

PRAC Led

**Xeljanz - tofacitinib -
EMA/H/C/004214/II/0052**

Pfizer Europe MA EEIG, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Peter Mol, “Submission of the final report from study A3921334 listed as a category 3 study in the RMP. This is a Non-Interventional Post-Authorisation Safety Study to evaluate the effectiveness of additional risk minimisation measures materials for tofacitinib in Europe via a survey of healthcare professionals.”

Opinion adopted on 31.08.2023.

Request for Supplementary Information adopted on 12.05.2023.

Positive Opinion adopted by consensus on 31.08.2023.

PRAC Led

**Xeljanz - tofacitinib -
EMA/H/C/004214/II/0054**

Pfizer Europe MA EEIG, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Peter Mol, “Submission of an updated RMP version 31.1 in order to modify study A3921427 from an interventional to a non-interventional study. In addition, the MAH has taken the opportunity to update other sections of the RMP.”

Request for Supplementary Information adopted on 31.08.2023.

Request for supplementary information adopted with a specific timetable.

PRAC Led

**Xofigo - radium-223 -
EMA/H/C/002653/II/0052**

Bayer AG, PRAC Rapporteur: Rugile Pilviniene, PRAC-CHMP liaison: Vilma Petrikaite, “Submission of the final report from study 20702/DIRECT listed as a category 3 study in the RMP. This is a non-interventional drug utilisation study to investigate the risk of off-

Positive Opinion adopted by consensus on 31.08.2023.

label use.”

Opinion adopted on 31.08.2023.

PRAC Led

WS2486

**Emtricitabine/Tenofovir disoproxil Zentiva-
EMA/H/C/004137/WS2486/0025**

Zentiva k.s., Generic, Generic of Truvada, Lead
PRAC Rapporteur: Ana Sofia Diniz Martins,
PRAC-CHMP liaison: Bruno Sepodes, “C.I.11.z -
To update the RMP for Emtricitabine/Tenofovir
disoproxil according to reference product
update, Truvada (EMA/H/C/WS2320).”

Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

PRAC Led

WS2535

Entresto-

EMA/H/C/004062/WS2535/0053

Neparvis-

EMA/H/C/004343/WS2535/0051

Novartis Europharm Limited, Lead PRAC
Rapporteur: Marie Louise Schougaard
Christiansen, PRAC-CHMP liaison: Thalia Marie
Estrup Blicher, “C.I.11.z - To provide a
consolidated RMP for Entresto and its duplicate
marketing authorisation Neparvis following
approval of:

- RMP version 4.2 (EMA/H/C/004062/X/0044/G
for Entresto and EMA/H/C/004343/X/0042/G
for Neparvis)

- RMP version 5.0

(EMA/H/C/004062/WS2434/G for Entresto and
EMA/H/C/004343/WS2434/G for Neparvis)

- RMP version 6.0 (EMA/H/C/004062/WS2465
for Entresto and EMA/H/C/004343/WS2465 for
Neparvis)”

Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on
31.08.2023.

PRAC Led

WS2537

Segluromet-

EMA/H/C/004314/WS2537/0021

Steglatro-

EMA/H/C/004315/WS2537/0020

Steglujan-

EMA/H/C/004313/WS2537/0024

Merck Sharp & Dohme B.V., Lead PRAC
Rapporteur: Menno van der Elst, PRAC-CHMP
liaison: Patrick Vrijlandt, “C.I.11.z - To provide
a new version of the RMP to update the final

Positive Opinion adopted by consensus on
31.08.2023.

study report date for study 8835-062 , following approval of the post-authorisation measure procedure EMEA/H/C/004313-5/MEA/002.5.”
Opinion adopted on 31.08.2023.

PRAC Led

WS2541

Ozempic-

EMEA/H/C/004174/WS2541/0040

Rybelsus-

EMEA/H/C/004953/WS2541/0035

Novo Nordisk A/S, Lead PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, “C.I.11.z - To update the RMP following assessment of the same for the reference product Wegovy (EMEA/H/C/005422/II/0009 approved on 28 April 2023). The Semaglutide RMP which is shared with all three Semaglutide products (Rybelsus, Ozempic, Wegovy) was updated due to an extension of the Wegovy label to include an indication in the adolescent population. The RMP's for Rybelsus (oral semaglutide for treatment of Type 2 Diabetes) and Ozempic (sc. semaglutide for treatment for Type 2 Diabetes) have been updated accordingly. Please note that no labelling changes will be made in this procedure because the investigation into efficacy and safety in pediatric population above 10 years of age according to agreed PIPs for Ozempic and Rybelsus is still ongoing.”
Opinion adopted on 31.08.2023.

Positive Opinion adopted by consensus on 31.08.2023.

PRAC Led

WS2546

Brimica Genuair-

EMEA/H/C/003969/WS2546/0039

Duaklir Genuair-

EMEA/H/C/003745/WS2546/0040

Covis Pharma Europe B.V., Lead PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, “C.I.11.z - To provide a new version of the RMP to update the milestone for PASS study D6560R00004 regarding Arrhythmia final report .”
Request for Supplementary Information adopted on 14.09.2023.

Request for supplementary information adopted with a specific timetable.

PRAC Led

WS2548

Bretaris Genuair-

EMEA/H/C/002706/WS2548/0051

Request for supplementary information adopted with a specific timetable.

Eklira Genuair-**EMA/H/C/002211/WS2548/0052**

Covis Pharma Europe B.V., Lead PRAC

Rapporteur: Adam Przybylkowski, PRAC-CHMP

liaison: Ewa Balkowiec Iskra, "C.I.11.z - To

provide a new version of the RMP to update the milestone for PASS study D6560R00004 regarding Arrhythmia final report ."

Request for Supplementary Information adopted on 14.09.2023.

B.5.5. CHMP-CAT assessed procedures**Alofisel - darvadstrocel -****EMA/H/C/004258/II/0044/G, Orphan, ATMP**

Takeda Pharma A/S, Rapporteur: Maria Luttgen, CHMP Coordinator: Kristina Dunder, "Grouped application comprising one type II variation and two type IB as follows:

- Update of section 4.8 of the SmPC in order to update the Summary of the safety profile and to add anal abscess, proctalgia and anal fistula to the list of adverse drug reactions on post-marketing experience following the assessment of R/0036 based on a review of the MAH's Global Safety Database.
- Update of section 4.2 of the SmPC in order to add the term Perilesional as an EDQM term, following the assessment of R/0036.
- Update of sections 1, 2.2, 3, 4.2, 6.5 and 6.6 of the SmPC in order to replace the term "suspension for injection" for "dispersion for injection", following the assessment of R/0036. The Annex A, Package Leaflet and Labelling are updated in accordance."

Opinion adopted on 14.09.2023, 08.09.2023.

Request for Supplementary Information adopted on 17.05.2023.

Positive Opinion adopted by consensus on 14.09.2023.

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel -**EMA/H/C/004731/II/0003, ATMP**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini

Opinion adopted on 14.09.2023, 08.09.2023.

Request for Supplementary Information adopted on 07.10.2022, 15.07.2022.

Positive Opinion adopted by consensus on 14.09.2023.

Breyanzi - lisocabtagene maraleucel /

Positive Opinion adopted by consensus on

<p>lisocabtagene maraleucel - EMA/H/C/004731/II/0021, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini, Opinion adopted on 14.09.2023, 08.09.2023. Request for Supplementary Information adopted on 14.07.2023.</p>	14.09.2023.
<p>Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMA/H/C/004731/II/0026/G, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini Request for Supplementary Information adopted on 08.09.2023.</p>	Request for supplementary information adopted with a specific timetable.
<p>Imlygic - talimogene laherparepvec - EMA/H/C/002771/II/0063, ATMP Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo, "Submission of the final report from study 20110261 listed as a category 3 study in the RMP. This is a Phase I, multi- centre, open-label, dose de-escalation study to evaluate the safety and efficacy of talimogene laherparepvec in paediatric subjects with advanced noncentral nervous system tumours that are amenable to direct injection." Opinion adopted on 14.09.2023, 08.09.2023.</p>	Positive Opinion adopted by consensus on 14.09.2023.
<p>Kymriah - tisagenlecleucel - EMA/H/C/004090/II/0072, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Request for Supplementary Information adopted on 08.09.2023.</p>	Request for supplementary information adopted with a specific timetable.
<p>Libmeldy - atidarsagene autotemcel - EMA/H/C/005321/II/0015, Orphan, ATMP Orchard Therapeutics (Netherlands) B.V., Rapporteur: Johannes Hendrikus Ovelgonne, CHMP Coordinator: Peter Mol Opinion adopted on 14.09.2023, 08.09.2023. Request for Supplementary Information adopted on 16.06.2023.</p>	Positive Opinion adopted by consensus on 14.09.2023.
<p>Upstaza - eladocagene exuparvovec - EMA/H/C/005352/II/0013, Orphan, ATMP</p>	Request for supplementary information adopted with a specific timetable.

PTC Therapeutics International Limited,
Rapporteur: Maura O'Donovan, CHMP
Coordinator: Finbarr Leacy
Request for Supplementary Information adopted
on 08.09.2023.

B.5.6. CHMP-PRAC-CAT assessed procedures

**Breyanzi - lisocabtagene maraleucel /
lisocabtagene maraleucel -
EMA/H/C/004731/II/0014, ATMP**

Positive Opinion adopted by consensus on
14.09.2023.

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Concetta Quintarelli, CHMP Coordinator: Paolo
Gasparini, PRAC Rapporteur: Gabriele Maurer,
"Update of sections 4.8 and 5.1 of the SmPC in
order to update efficacy information based on
final results from studies 017001 and JCAR-017-
BCM-001 listed as obligations in the Annex II.
These studies aimed to further characterise the
long-term efficacy and safety of Breyanzi in
patients treated with relapsed or refractory
DLBCL, PMBCL, FL3B after two or more lines of
systemic therapy. Study 017001 is a phase 1,
open-label, single-arm, multicohort,
multicenter, seamless design trial, while study
JCAR-017-BCM-001 is a phase 2, open-label,
single-arm, multicohort, multicenter trial. The
Annex II is updated accordingly. The RMP
version 3.0 has also been submitted."
Opinion adopted on 14.09.2023, 08.09.2023.
Request for Supplementary Information adopted
on 24.03.2023.

**Zolgensma - onasemnogene abeparvovec -
EMA/H/C/004750/II/0040, Orphan,
ATMP**

Positive Opinion adopted by consensus on
14.09.2023.

Novartis Europharm Limited, Rapporteur:
Johannes Hendrikus Ovelgonne, CHMP
Coordinator: Peter Mol, PRAC Rapporteur: Ulla
Wändel Liminga, "Update of section 4.4 of the
SmPC in order to add a new warning and
precaution capturing the theoretical risk of
tumorigenicity as a result of vector integration
and to include a new statement indicating
random instances of vector integration are
possible; based on final results from studies
2220205 and 2220117, and literature. The
Package Leaflet is updated accordingly. The RMP
version 3 has also been submitted."
Opinion adopted on 14.09.2023, 08.09.2023.
Request for Supplementary Information adopted

on 14.07.2023.

B.5.7. PRAC assessed ATMP procedures

PRAC Led
Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0064, ATMP
Amgen Europe B.V, CHMP Coordinator: Johanna Lähteenvuo, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of an updated RMP version 11.0 in order to remove the important potential risk of "talimogene laherparepvec-mediated anti-GM-CSF antibody response", based on the accumulated scientific and clinical data."
Opinion adopted on 08.09.2023.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2470/G
Ambirix-
EMEA/H/C/000426/WS2470/0129/G
Cervarix-
EMEA/H/C/000721/WS2470/0123/G
Infanrix hexa-
EMEA/H/C/000296/WS2470/0332/G
Twinrix Adult-
EMEA/H/C/000112/WS2470/0164/G
Twinrix Paediatric-
EMEA/H/C/000129/WS2470/0165/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke
Opinion adopted on 31.08.2023.

WS2484
Filgrastim Hexal-
EMEA/H/C/000918/WS2484/0071
Zarzio-EMEA/H/C/000917/WS2484/0072
Sandoz GmbH, Lead Rapporteur: Peter Mol
Opinion adopted on 31.08.2023.
Request for Supplementary Information adopted on 22.06.2023.

WS2494/G
Ozempic-
EMEA/H/C/004174/WS2494/0039/G
Wegovy-
EMEA/H/C/005422/WS2494/0013/G
Novo Nordisk A/S, Lead Rapporteur: Patrick Vrijlandt
Opinion adopted on 31.08.2023.

<p>WS2506/G Filgrastim Hexal- EMA/H/C/000918/WS2506/0073/G Zarzio- EMA/H/C/000917/WS2506/0074/G Sandoz GmbH, Lead Rapporteur: Peter Mol Opinion adopted on 31.08.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>
<p>WS2511/G Entresto- EMA/H/C/004062/WS2511/0052/G Neparvis- EMA/H/C/004343/WS2511/0050/G Novartis Europharm Limited, Lead Rapporteur: Patrick Vrijlandt Opinion adopted on 31.08.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>
<p>WS2514 Herceptin- EMA/H/C/000278/WS2514/0190 MabThera- EMA/H/C/000165/WS2514/0198 Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 31.08.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>
<p>WS2516 Revatio- EMA/H/C/000638/WS2516/0105 Viagra-EMA/H/C/000202/WS2516/0118 Upjohn EESV, Lead Rapporteur: Patrick Vrijlandt Opinion adopted on 31.08.2023.</p>	<p>Positive Opinion adopted by consensus on 31.08.2023.</p>
<p>WS2521 Riltrava Aerosphere- EMA/H/C/005311/WS2521/0007 Trixeo Aerosphere- EMA/H/C/004983/WS2521/0014 AstraZeneca AB, Lead Rapporteur: Finbarr Leacy, "C.I.z - To submit the new results for the conducted fish full life-cycle study for budesonide and an updated Environmental Risk Assessment (ERA) report." Request for Supplementary Information adopted on 31.08.2023.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>WS2524 Galvus-EMA/H/C/000771/WS2524/0079 Jalra-EMA/H/C/001048/WS2524/0082 Xiliarx-EMA/H/C/001051/WS2524/0080 Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "C.I.z - To provide an updated Environmental Risk Assessment (ERA) report for</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

OECD TG308 and OECD TG218 studies.”
Request for Supplementary Information adopted
on 31.08.2023.

WS2528/G

Eucreas-

EMA/H/C/000807/WS2528/0101/G

Icandra-

EMA/H/C/001050/WS2528/0106/G

Zomarist-

EMA/H/C/001049/WS2528/0103/G

Novartis Europharm Limited, Lead Rapporteur:
Kristina Dunder, “C.I.z - To provide the
Environmental Risk Assessment (ERA) report for
vildagliptin to add data from OECD TG308 and
OECD TG218 studies.

C.I.z - To provide the Environmental Risk
Assessment (ERA) report for metformin to add
FOCUS_DEGKINv2 SFO calculated DT50 values.”
Request for Supplementary Information adopted
on 31.08.2023.

Request for supplementary information adopted
with a specific timetable.

WS2530

Filgrastim Hexal-

EMA/H/C/000918/WS2530/0072

Zarzio-EMA/H/C/000917/WS2530/0073

Sandoz GmbH, Lead Rapporteur: Peter Mol,
“C.I.2.a - To update the Product information of
Zarzio and Filgrastim Hexal in line with the
reference product, Neupogen, following the
detection of discrepancies during a full review.
Furthermore, the MAH is taking the opportunity
to implement the ‘Excipients in the labelling and
package leaflet of medicinal products for human
use’ guideline (SANTE- 2017-11668)
(EMA/CHMP/302620/2017 Rev. 2; 12.09.2022)
regarding the excipient “Sodium”; and update
the Instruction for Use (IFU) to include a
warning about dropping the product.”
Opinion adopted on 14.09.2023.

Positive Opinion adopted by consensus on
14.09.2023.

WS2536

Rixathon-

EMA/H/C/003903/WS2536/0067

Riximyo-

EMA/H/C/004729/WS2536/0068

Sandoz GmbH, Lead Rapporteur: Jan Mueller-
Berghaus
Request for Supplementary Information adopted
on 14.09.2023.

Request for supplementary information adopted
with a specific timetable.

WS2539

Positive Opinion adopted by consensus on

Lantus-EMEA/H/C/000284/WS2539/0128 07.09.2023.
Suliqua-EMEA/H/C/004243/WS2539/0034
Toujeo-EMEA/H/C/000309/WS2539/0124
Sanofi-Aventis Deutschland GmbH, Lead
Rapporteur: Kristina Dunder
Opinion adopted on 07.09.2023.

WS2545/G Positive Opinion adopted by consensus on
Januvia- 14.09.2023.
EMEA/H/C/000722/WS2545/0083/G
Ristaben-
EMEA/H/C/001234/WS2545/0077/G
TESAVEL-
EMEA/H/C/000910/WS2545/0083/G
Xelevia-
EMEA/H/C/000762/WS2545/0091/G
Merck Sharp & Dohme B.V., Lead Rapporteur:
Patrick Vrijlandt
Opinion adopted on 14.09.2023.
Request for Supplementary Information adopted
on 10.08.2023.

B.5.9. Information on withdrawn type II variation / WS procedure

VidPrevtyl Beta - SARS-CoV-2, B.1.351 The MAH withdrew the type II variation
variant, prefusion Spike delta TM protein, application on 24.08.2023.
recombinant - EMEA/H/C/005754/II/0003
Sanofi Pasteur, Rapporteur: Jan Mueller-
Berghaus
Request for Supplementary Information adopted
on 20.07.2023, 01.06.2023.

Azacitidine betapharm - azacitidine - The MAH withdrew the procedure on
EMEA/H/C/005075/II/0016 18.08.2023.
betapharm Arzneimittel GmbH, Generic, Generic
of Vidaza, Rapporteur: Petr Vrbata
Request for Supplementary Information adopted
on 22.06.2023.
Withdrawal request submitted on 18.08.2023.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

aztreonam / avibactam - Accelerated review
EMEA/H/C/006113
treatment of infections (cIAI, HAP, VAP, and

cUTI), and aerobic Gram-negative infections with limited treatment options

in vitro diagnostic medical device -

EMA/H/D/006372

next generation sequencing (NGS) assay for tumor mutation profiling

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

polihexanide - EMA/H/C/005858, Orphan

SIFI SPA, treatment of acanthamoeba keratitis
List of Questions adopted on 15.09.2022.

Azacitidine Accord - azacitidine -

EMA/H/C/005147/X/0013

Accord Healthcare S.L.U., Generic, Generic of Vidaza, Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Menno van der Elst, "Extension application to introduce a new pharmaceutical form associated with a new strength (10 mg/ml powder for solution for infusion) and a new route of administration (intravenous use).

The RMP version 2 is updated in accordance."
List of Questions adopted on 26.04.2023.

Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMA/H/C/006052

active immunisation for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine
List of Questions adopted on 26.04.2023.

cefepime / enmetazobactam -

EMA/H/C/005431

treatment of: 1) complicated urinary tract infections (including pyelonephritis); 2) hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); 3) patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above and 4) infections due to aerobic Gram-negative organisms in adults with limited treatment options

List of Questions adopted on 25.05.2023.

**Pandemic influenza vaccine (H5N1)
(surface antigen, inactivated, adjuvanted,
prepared in cell cultures) -
EMA/H/C/006051**

prophylaxis of influenza

List of Questions adopted on 26.04.2023.

catumaxomab - EMA/H/C/005697

indicated for the treatment of malignant ascites

List of Questions adopted on 15.12.2022.

lecanemab - EMA/H/C/005966

a disease modifying treatment in adult patients
with Mild Cognitive Impairment due to
Alzheimer's disease and Mild Alzheimer's
disease (Early Alzheimer's disease)

List of Questions adopted on 25.05.2023.

bevacizumab - EMA/H/C/005723

Treatment of neovascular (wet) age-related
macular degeneration (nAMD).

List of Questions adopted on 26.04.2023.

paliperidone - EMA/H/C/006185

Treatment of schizophrenia

List of Questions adopted on 25.05.2023.

pomalidomide - EMA/H/C/006195

in combination with dexamethasone is indicated
in the treatment of adult patients with relapsed
and refractory multiple myeloma (MM)

List of Questions adopted on 20.07.2023.

Uptravi - selezipag -

EMA/H/C/003774/X/0038

Janssen-Cilag International N.V., Rapporteur:
Martina Weise, PRAC Rapporteur: Nathalie
Gault, "Extension application to add a new
strength of 100 µg film-coated tablets in HDPE
bottle.

The RMP (version 10.1) is updated in
accordance."

List of Questions adopted on 22.06.2023.

danicopan - EMA/H/C/005517, Orphan

Alexion Europe, Treatment of extravascular
haemolysis (EVH) in patients with paroxysmal
nocturnal haemoglobinuria

List of Questions adopted on 20.07.2023.

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) -

EMA/H/C/001206/II/0086/G

GlaxoSmithkline Biologicals SA, Informed Consent of Pandemrix (EXP), Rapporteur: Patrick Vrijlandt

Briumvi - ublituximab -

EMA/H/C/005914/II/0001

Propharma Group The Netherlands B.V., Rapporteur: Ewa Balkowiec Iskra

Cosentyx - secukinumab -

EMA/H/C/003729/II/0107

Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola

Flucelvax Tetra - influenza vaccine (surface antigen, inactivated, prepared in cell cultures) - EMA/H/C/004814/II/0041

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

Hemlibra - emicizumab -

EMA/H/C/004406/II/0037

Roche Registration GmbH, Rapporteur: Alexandre Moreau

Hizentra - human normal immunoglobulin -

EMA/H/C/002127/II/0146/G

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Nimenrix - meningococcal group A, C, W135 and Y conjugate vaccine -

EMA/H/C/002226/II/0129/G

Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang

Nplate - romiplostim -

EMA/H/C/000942/II/0089

Amgen Europe B.V., Rapporteur: Maria
Concepcion Prieto Yerro

Omnitrope - somatropin -**EMA/H/C/000607/II/0076**

Sandoz GmbH, Rapporteur: Patrick Vrijlandt

Ontruzant - trastuzumab -**EMA/H/C/004323/II/0048/G**

Samsung Bioepis NL B.V., Rapporteur: Karin
Janssen van Doorn

Palynziq - pegvaliase -**EMA/H/C/004744/II/0039/G, Orphan**

BioMarin International Limited, Rapporteur:
Patrick Vrijlandt

Phesgo - pertuzumab / trastuzumab -**EMA/H/C/005386/II/0020/G**

Roche Registration GmbH, Rapporteur: Aaron
Sosa Mejia

Pyrukynd - mitapivat -**EMA/H/C/005540/II/0003/G, Orphan**

Agios Netherlands B.V., Rapporteur: Alexandre
Moreau

Shingrix - herpes zoster vaccine**(recombinant, adjuvanted) -****EMA/H/C/004336/II/0068**

GlaxoSmithkline Biologicals SA, Rapporteur:
Christophe Focke

Strensiq - asfotase alfa -**EMA/H/C/003794/II/0065/G, Orphan**

Alexion Europe SAS, Rapporteur: Paolo
Gasparini

Toujeo - insulin glargine -**EMA/H/C/000309/II/0127/G**

Sanofi-Aventis Deutschland GmbH, Duplicate,
Duplicate of Lantus, Rapporteur: Patrick
Vrijlandt

**Vaxelis - diphtheria, tetanus, pertussis
(acellular, component), hepatitis B (rDNA),
poliomyelitis (inact.) and haemophilus type
B conjugate vaccine (adsorbed) -****EMA/H/C/003982/II/0132**

MCM Vaccine B.V., Rapporteur: Christophe
Focke

XGEVA - denosumab -**EMA/H/C/002173/II/0082/G**

Amgen Europe B.V., Rapporteur: Kristina Dunder

Zaltrap - aflibercept -

EMA/H/C/002532/II/0069/G

Sanofi Winthrop Industrie, Rapporteur: Filip Josephson

WS2547

Blitzima-

EMA/H/C/004723/WS2547/0068

Truxima-

EMA/H/C/004112/WS2547/0071

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

AREXVY - respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E -

EMA/H/C/006054/II/0002/G

GlaxoSmithkline Biologicals S.A., Rapporteur: Patrick Vrijlandt, "Update of section 4.5 of the SmPC in order to update information on the co-administration with inactivated seasonal quadrivalent influenza vaccines: with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV) based on final results from studies RSV OA=ADJ-008 and RSV OA=ADJ-017. These are Phase III studies intended to evaluate the immune response, safety and reactogenicity of Arexvy when co-administered with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV), respectively."

Caprelsa - vandetanib -

EMA/H/C/002315/II/0059

Sanofi B.V., Rapporteur: Alexandre Moreau, "Update of section 5.1 of the SmPC in order to update information on long-term use, based on a safety evaluation report."

COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) -

EMA/H/C/005735/II/0187

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Submission of the final report"

from study BNT162-01, a multi-site, open-label, first-in-human (FIH), Phase 1/2, two-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults, listed as category 3 study in the RMP.”

**Dynastat - parecoxib -
EMA/H/C/000381/II/0088**

Pfizer Europe MA EEIG, Duplicate, Duplicate of Xapit (SRD), Rapporteur: Finbarr Leacy, “Update of section 4.4 of the SmPC in order to update skin reactions information based on literature and post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to align the Package Leaflet with the SmPC.”

**Fabrazyme - agalsidase beta -
EMA/H/C/000370/II/0129**

Sanofi B.V., Rapporteur: Patrick Vrijlandt, “Update of section 4.6 of the SmPC in order to update the safety information on pregnancy and breast-feeding based on results from AGAL02603/MS12868: “A Multicenter, Multinational Study of the Effects of Fabrazyme (agalsidase beta) Treatment on Lactation and Infants”, listed as a category 3 study in the RMP, MAH safety database and literature search; the Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce minor editorial changes to the PI.”

**IMCIVREE - setmelanotide -
EMA/H/C/005089/II/0015, Orphan**

Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn, “Submission of the final report from study RM-493-014. This is a phase 2 treatment trial of setmelanotide in patients with rare genetic disorders of obesity.”

**NUVAXOVID - covid-19 vaccine
(recombinant, adjuvanted) -
EMA/H/C/005808/II/0058/G**

Novavax CZ, a.s., Rapporteur: Patrick Vrijlandt

**Paxlovid - nirmatrelvir / ritonavir -
EMA/H/C/005973/II/0049/G**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel

Race, "Grouped application comprising two type II variations (C.I.4) as follows:

- Update of sections 4.4 and 4.8 of the SmPC in order to clarify that toxic epidermal necrolysis has been reported with Paxlovid and to add toxic epidermal necrolysis to the list of adverse drug reactions (ADRs) with frequency Rare based on the cumulative review of MAH safety database and literature.

- Update of sections 4.4 and 4.8 of the SmPC in order to clarify that Stevens-Johnson syndrome has been reported with Paxlovid and to add Stevens-Johnson syndrome to the list of adverse drug reactions (ADRs) with frequency Rare, based on the cumulative review of MAH safety database and literature.

The Package Leaflet is updated accordingly."

Phesgo - pertuzumab / trastuzumab -

EMA/H/C/005386/II/0021

Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, "Submission of the final report from study MO40628 (PHranceSCa), a Phase II, randomized, multicenter, open-label, cross-over study to evaluate patient reported preference for Phesgo compared with intravenous pertuzumab and trastuzumab in patients with HER2-positive EBC."

RAYVOW - lasmiditan -

EMA/H/C/005332/II/0004

Eli Lilly Nederland B.V., Rapporteur: Janet Koenig, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with dabigatran and rosuvastatin based on the results from study LAIO, An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers. The aim of study LAIO was to investigate the effect of lasmiditan on the pharmacokinetic profiles of dabigatran (a P-glycoprotein substrate) and rosuvastatin (breast cancer resistance protein substrate) in healthy volunteers. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

RINVOQ - upadacitinib -

EMA/H/C/004760/II/0042

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Kristina Dunder, "Submission of the final report from study M13-545 listed as a category 3 study in the RMP (MEA/10). This is a Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis."

**Tremelimumab AstraZeneca -
tremelimumab -
EMA/H/C/004650/II/0002**

AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the paediatric information based on final results from study D419EC00001; this is a Phase I/II, open-label, multicenter study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in paediatric patients with advanced solid tumours and haematological malignancies."

**VidPrevtyn Beta - SARS-CoV-2, B.1.351
variant, prefusion Spike delta TM protein,
recombinant - EMA/H/C/005754/II/0006**

Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to add 'Hypersensitivity and anaphylactic reactions' to the list of adverse drug reactions (ADRs) with frequency 'Not known', based on post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI."

**Zavicefta - ceftazidime / avibactam -
EMA/H/C/004027/II/0033**

Pfizer Ireland Pharmaceuticals, Rapporteur: Ingrid Wang, "Update of section 4.8 of the SmPC in order to add 'Kounis syndrome' to the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH is taking the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet."

**WS2543
Imfinzi-EMA/H/C/004771/WS2543/0062**

IMJUDO-**EMA/H/C/006016/WS2543/0003**

AstraZeneca AB, Lead Rapporteur: Aaron Sosa Mejia, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to include paediatric information based on final results from study D419EC00001 "Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies". In addition, the MAH took this opportunity to introduce editorial changes."

B.6.10. CHMP-PRAC assessed procedures

COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) -**EMA/H/C/005735/II/0188/G**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, "Grouped application comprising two type II variations as follows:

C.I.4 – Update of section 4.8 of the SmPC in order to update the safety information based on interim (6MPD3 in 12-15yo) and final results from study C4591001, listed as a category 3 study in the RMP. This is a Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals. An updated RMP version 10.1 has also been submitted.

C.I.11.b - Submission of an updated RMP version 10.1 in order to revise RMP milestones of final study reports of other on-going procedures, including other administrative and editorial changes."

Onglyza - saxagliptin -**EMA/H/C/001039/II/0057**

AstraZeneca AB, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update safety, efficacy and pharmacokinetic information in paediatric patients with Type 2 diabetes mellitus (T2DM)

aged 10 to <18 years of age based on interim results from study D1680C00019 (T2NOW). This is a 26-week, multicentre, randomised, placebo-controlled, double-blind, parallel group, Phase III trial with a 26-week safety extension period evaluating the safety and efficacy of dapagliflozin (5 and 10 mg), and, separately, saxagliptin (2.5 and 5 mg) in paediatric patients with T2DM who were between 10 and below 18 years of age. The Package Leaflet is updated accordingly. The RMP version 17.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template and to introduce editorial changes.”

**Pradaxa - dabigatran etexilate -
EMA/H/C/000829/II/0147/G**

Boehringer Ingelheim International GmbH,
Rapporteur: Thalia Marie Estrup Blicher, PRAC
Rapporteur: Marie Louise Schougaard
Christiansen, “A Grouped application consisting of:

C.I.7.a (type IB): to delete the pharmaceutical form “powder and solvent for oral solution, 6.25 mg/ml”, as agreed in procedure
EMA/H/C/000829/II/0144.

C.I.4 (type II): Update of section 4.1 of the SmPC in order to modify the indication following the deletion of the powder and solvent for oral solution; the Package Leaflet is updated accordingly. The RMP version 41.2 has also been submitted.

In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet.”

**Prolia - denosumab -
EMA/H/C/001120/II/0099**

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, “Update of sections 4.4 and 4.8 of the SmPC in order to update a warning regarding hypocalcaemia and to include reports of life-threatening events and fatal cases occurred in the post-marketing setting, particularly in patients with severe renal impairment, receiving dialysis or treatment with other calcium lowering drugs based on the cumulative review of MAH safety database and literature. The Package Leaflet is updated

accordingly. The RMP version 32.0 has also been submitted.”

**Reagila - cariprazine -
EMA/H/C/002770/II/0034**

Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of sections 4.3 and 4.5 of the SmPC in order to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on final results from study RGH-188-301 (CYPRESS) listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

B.6.11. PRAC assessed procedures

PRAC Led

**Benlysta - belimumab -
EMA/H/C/002015/II/0116**

GlaxoSmithKline (Ireland) Limited, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, “Submission of the final report for the Belimumab Pregnancy registry (BEL114256) listed as a category 3 study in the RMP. This is a non-interventional study to evaluate pregnancy and infant outcomes for pregnancies in women with systemic lupus erythematosus (SLE) exposed to commercially supplied belimumab within the 4 months preconception and/or during pregnancy. In addition, the BPR protocol planned to collect pregnancy and infant outcomes for pregnancies in women with SLE and SABLE (Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus) protocol who were not exposed to belimumab and enrolled in BPR. The RMP version 45.0 has also been submitted.”

PRAC Led

**Lenvima - lenvatinib -
EMA/H/C/003727/II/0053**

Eisai GmbH, PRAC Rapporteur: Ulla Wändel

Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update safety and efficacy information for the hepatocellular carcinoma (HCC) indication, based on interim results from study E7080-M000-508 (STELLAR), listed as a category 3 PASS in the RMP. This is a non-interventional multicentre, observational, phase 4 study to evaluate the safety and tolerability of lenvatinib in patients with advanced or unresectable HCC. RMP version 15.2 has also been submitted."

PRAC Led

**Remicade - infliximab -
EMA/H/C/000240/II/0243**

Janssen Biologics B.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "To update section 4.8 of the SmPC to add weight increased to the list of adverse drug reactions (ADRs) with frequency Uncommon following PRAC PSUR assessment report (EMA/PRAC/158162/2023-Corr.1) based on the cumulative literature review.

The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce minor editorial changes."

PRAC Led

**Spikevax - covid-19 mrna vaccine
(nucleoside-modified) -
EMA/H/C/005791/II/0110**

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of the final report from study P903 - US PASS (Post Authorisation Safety in the US Study, NCT04958954), listed as a category 3 study in the RMP: Post-marketing safety of SARS-CoV-2 Spikevax vaccine in the US: Active surveillance, signal refinement and self-controlled risk interval (SCRI) signal evaluation in HealthVerity. This submission addresses the post-authorisation measure MEA/003."

PRAC Led

**WS2515
Lacosamide UCB-
EMA/H/C/005243/WS2515/0018
Vimpat-EMA/H/C/000863/WS2515/0100**

UCB Pharma S.A., Lead PRAC Rapporteur: Ulla Wandel Liminga, PRAC-CHMP liaison: Filip

Josephson, "Submission of an updated RMP version 17.0 in order to introduce new updates including the removal of category 3 study EP0158 due to study closure by lack of enrolment, and the removal of category 3 studies (SP848 and EP0034)."

PRAC Led

WS2519/G

Advagraf-

EMA/H/C/000712/WS2519/0071/G

Modigraf-

EMA/H/C/000954/WS2519/0046/G

Astellas Pharma Europe B.V., Lead PRAC
Rapporteur: Eamon O Murchu, PRAC-CHMP
liaison: Jayne Crowe, "A grouped application consisting of:

Type II (C.I.13): Submission of the final report from study F506-PV-0001 listed as a category 3 study in the RMP for Advagraf and Modigraf. This is a non-interventional post-authorisation safety study (NI-PASS) of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from Transplant Pregnancy Registry International (TPRI). The RMP version 5.0 has also been submitted.

Type IB (C.I.11.z): To include the feasibility assessment of using alternative secondary-use data sources to replicate the Transplant Pregnancy Registry International (TPRI) study as a category 3 additional pharmacovigilance activity in the RMP, including the milestones for the progress report and the final report of the feasibility assessment, related to EMA/H/C/000712/MEA/032 and EMA/H/C/000954/MEA/024."

B.6.12. CHMP-CAT assessed procedures

**Hemgenix - etranacogene dezaparvovec -
EMA/H/C/004827/II/0009/G, Orphan,
ATMP**

CSL Behring GmbH, Rapporteur: Silke Dorner,
CHMP Coordinator: Daniela Philadelphia

**Kymriah - tisagenlecleucel -
EMA/H/C/004090/II/0071, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Rune
Kjeken, CHMP Coordinator: Ingrid Wang,

“Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study CCTL019B2202 (a phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia). Submission of cellular kinetic report for the B-cell acute lymphoblastic leukaemia (ALL) indication based on data from pivotal study CCTL019B2202 and the supportive study CCTL019B2205J involving paediatric ALL patients (partially fulfil REC). In addition, the MAH took this opportunity to introduce editorial changes.”

ROCTAVIAN - valoctocogene roxaparvovec - EMEA/H/C/005830/II/0008/G, Orphan, ATMP

BioMarin International Limited, Rapporteur:
Violaine Closson Carella, CHMP Coordinator:

Jean-Michel Race, “Grouped application comprising two variations as follows:

C.I.4 - Update of section 4.5 of the SmPC in order to add drug-drug interaction information with Isotretinoin and Efavirenz based on results from study “In vitro Drug-Drug Interaction Study: Effects of Concomitant Administration of Isotretinoin, Amphetamine, Omeprazole, Celecoxib and Selected HAART Medications with AAV5-FVIII-SQ on Cytotoxicity and AAV5-FVIII-SQ DNA and RNA Expression in Primary Human Hepatocytes”.

A.6 - To change the ATC Code from B02BD1 to “not yet assigned”.”

WS2558/G

Tecartus-

EMEA/H/C/005102/WS2558/0036/G

Yescarta-

EMEA/H/C/004480/WS2558/0064/G

Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

B.6.13. CHMP-PRAC-CAT assessed procedures

Kymriah - tisagenlecleucel -

EMEA/H/C/004090/II/0075, Orphan,

ATMP

Novartis Europharm Limited, Rapporteur: Rune

Kjeken, CHMP Coordinator: Ingrid Wang, PRAC
Rapporteur: Gabriele Maurer, "Update of
sections 5.1 and 5.2 of the SmPC in order to
update efficacy and pharmacokinetic
information based on final results from study
CCTL019C2201 PAES in the Annex II (ANX008);
this is a Phase II, single arm, multicenter trial to
determine the efficacy and safety of CTL019 in
adult patients with relapsed or refractory diffuse
large B-cell lymphoma (DLBCL). The RMP
version 6 has also been submitted. In addition,
the MAH took the opportunity to update Annex
II.D of the PI."

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2527/G

Infanrix hexa-

EMA/H/C/000296/WS2527/0334/G

GlaxoSmithkline Biologicals SA, Lead

Rapporteur: Christophe Focke

WS2553/G

Delstrigo-

EMA/H/C/004746/WS2553/0036/G

Pifeltro-

EMA/H/C/004747/WS2553/0028/G

Merck Sharp & Dohme B.V., Lead Rapporteur:

Filip Josephson

WS2562

Nilemdo-

EMA/H/C/004958/WS2562/0032

Nustendi-

EMA/H/C/004959/WS2562/0036

Daiichi Sankyo Europe GmbH, Lead Rapporteur:

Patrick Vrijlandt

WS2565

Blitzima-

EMA/H/C/004723/WS2565/0069

Truxima-

EMA/H/C/004112/WS2565/0072

Celltrion Healthcare Hungary Kft., Lead

Rapporteur: Sol Ruiz

WS2567

Glyxambi-

EMA/H/C/003833/WS2567/0054

Synjardy-

EMEA/H/C/003770/WS2567/0075

Boehringer Ingelheim International GmbH, Lead
Rapporteur: Patrick Vrijlandt

WS2568**Nuwiq-EMEA/H/C/002813/WS2568/0055**

Vihuma-

EMEA/H/C/004459/WS2568/0037

Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus

WS2570**Lantus-EMEA/H/C/000284/WS2570/0131****Suliqua-EMEA/H/C/004243/WS2570/0036****Toujeo-EMEA/H/C/000309/WS2570/0126**

Sanofi-Aventis Deutschland GmbH, Lead
Rapporteur: Patrick Vrijlandt

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY**B.7.1. Yearly Line listing for Type I and II variations****B.7.2. Monthly Line listing for Type I variations****B.7.3. Opinion on Marketing Authorisation transfer (MMD only)****B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)****B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)****B.7.6. Notifications of Type I Variations (MMD only)****C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)****D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)****E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES**

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 11-14 September 2023 CHMP plenary:

Infectious Diseases

Treatment of sepsis and septic shock (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary reports.
--	--

Treatment of infections due to Acinetobacter baumannii-calcoaceticus complex (ABC)	The CHMP denied eligibility to PRIME and adopted the critical summary reports.
--	--

Oncology

Treatment of adult patients with relapsed or refractory multiple myeloma who have received four or more classes of prior therapies ATMP	The CHMP denied eligibility to PRIME and adopted the critical summary reports.
---	--

Iopofosine I-131 Treatment of patients with Waldenström's macroglobulinemia (WM) who received at least two prior lines of therapy (SME)	The CHMP granted eligibility to PRIME and adopted the critical summary report.
--	--

Gastroenterology-Hepatology

Treatment of Acute-on-chronic liver failure (ACLF) (SME)ATMP	The CHMP denied eligibility to PRIME and adopted the critical summary reports.
--	--

Neurology

Treatment of Amyotrophic Lateral Sclerosis (SME)

The CHMP denied eligibility to PRIME and adopted the critical summary reports.

G.2.2. List of procedures starting in September 2023 for October 2023 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address